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 2 
Abstract 3 
Atrial fibrillation (AF) is a common arrhythmia and major healthcare problem 4 
associated with increased morbidity and mortality. Several risk factors, triggers and 5 
medical disorders have been identified in the development of this arrhythmia.  6 
To address this issue, a Task Force was convened by the European Heart Rhythm 7 
Association (EHRA) and the European Association of Cardiovascular Prevention and 8 
Rehabilitation (EACPR), endorsed by the Heart Rhythm Society (HRS) and Asia-9 
Pacific Heart Rhythm Society (APHRS), with the remit to comprehensively review 10 
the published evidence available, to publish a joint consensus document on the 11 
prevention of AF, and to provide up-to-date consensus recommendations for use in 12 
clinical practice.  In this document, our aim is to summarize the association of each 13 
modifiable risk factor associated with AF and the available data on the impact of 14 
possible interventions directed at these factors in preventing or reducing the burden of 15 
AF. 16 
 17 
Key Words: Arrhythmias, Atrial Fibrillation, Prevention, Risk Factors, Obesity, 18 
Hyperlipidemia, Diet, Caffeine, Alcohol, Obstructive Sleep Apnea, Diabetes, 19 
Hypertension, Smoking, Air Pollution, Recreational Drugs, Psychological Distress, 20 
Physical Activity, Genetic Predisposition, Hyperthyroidism, Supraventricular 21 
Arrhythmias, Post-Operative Atrial Fibrillation, Therapy, Stroke, Patient preferences, 22 
Health Economics, Medications 23 
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Abbreviations and acronyms 1 
ACEI –angiotensin converting enzyme inhibitors  2 
AF - atrial fibrillation 3 
ARB- angiotensin receptor blockers 4 
AVNRT - atrioventricular nodal re-entry tachycardia  5 
BMI – body mass index 6 
CHADS2 – cardiac failure, hypertension, age, diabetes, stroke (doubled) 7 
CHA2DS2-VASc – Congestive heart failure or left ventricular dysfunction, 8 
Hypertension, Age ≥75 (doubled), Diabetes, Stroke/Transient Ischaemic Attack 9 
(doubled)-Vascular Disease, Age 65-74, Sex category (female) 10 
CI – confidence interval 11 
FU – follow-up 12 
HR – hazard ratio 13 
HDL - high-density lipoprotein cholesterol  14 
ICD - implantable cardioverter defibrillators 15 
LA – left atrium 16 
LDL -low-density lipoprotein cholesterol 17 
LV – left ventricle 18 
NOAC - non-VKA oral anticoagulant 19 
OAC – oral anticoagulation 20 
OR – odds ratio 21 
OSA – obstructive sleep apnea 22 
n3-PUFA -omega-3 polyunsaturated fatty acids 23 
RAAS- renin-angiotensin-aldosterone system 24 
RR-relative risk 25 
SBP - systolic blood pressure  26 
SAMe-TT2R2 - Sex (female), Age (<60 years), Medical history, Treatment 27 
(interacting drugs, e.g. amiodarone for rhythm control), Tobacco use (within 2 years) 28 
(doubled), Race (non-Caucasian) (doubled) 29 
SVT - supraventricular tachyarrhythmia 30 
VKA – vitamin K antagonist 31 
 Page 6 of 82 
   Introduction 32 
Atrial fibrillation (AF) is an important and highly prevalent arrhythmia, which is associated with 33 
significantly increased morbidity and mortality, including a 4- to 5-fold increased risk for stroke (1, 2), a 2-34 
fold increased risk for dementia (3, 4), a 3-fold risk for heart failure (2), a 2-fold increased risk for 35 
myocardial infarction (5, 6), and a 40% to 90% increased  risk for overall mortality (2, 7). The constantly 36 
increasing number of AF patients and recognition of increased morbidity, mortality, impaired quality of life, 37 
safety issues and side effects of rhythm control strategies with antiarrhythmic drugs, and high health care 38 
costs associated with AF have spurred numerous investigations to develop more effective treatments for AF 39 
and its complications (8). Although AF treatment has been studied extensively, AF prevention has received 40 
relatively little attention, while it has paramount importance in prevention of morbidity and mortality, and 41 
complications associated with arrhythmia and its treatment. Current evidence shows a clear association 42 
between the presence of modifiable risk factors and the risk of developing AF. 43 
By implementing AF risk reduction strategies aiming at risk factors such as obesity, hypertension, 44 
diabetes and obstructive sleep apnea, which are interrelated, we impact upon the escalating incidence of AF 45 
in the population and ultimately decrease the healthcare burden of associated co-morbidities of AF.  46 
To address this issue, a Task Force was convened by the European Heart Rhythm Association 47 
(EHRA) and the European Association of Cardiovascular Prevention and Rehabilitation (EACPR), endorsed 48 
by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS), with the remit to 49 
comprehensively review the published evidence available, to publish a joint consensus document on the 50 
prevention of AF, and to provide up-to-date consensus recommendations for
 
use in clinical practice.  In this 51 
document, our aim is to summarize the current evidence on the association of each modifiable risk factor 52 
with AF and the available data on the impact of possible interventions directed at these factors in preventing 53 
or reducing the burden of AF. While the evidence on AF prevention is still emerging, the topic is not fully 54 
covered in current guidelines and some aspects are still controversial. Therefore, there is a need to provide 55 
expert recommendations for professionals participating in the care of at-risk patients and populations, with 56 
respect to addressing risk factors and lifestyle modifications.   57 
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 58 
Health economic considerations 59 
Atrial fibrillation is a costly disease, both in terms of direct, and indirect costs, the former being 60 
reported by cost of illness studies as per-patient annual costs in the range of US $2000 to 14 200 in North 61 
America and of €450 to 3000 in Europe (9).  62 
In individuals with AF or at risk of developing AF, any effective preventive measure, intervention on 63 
modifiable risk factors or co-morbidities, as well as any effective pharmacological or non-pharmacological 64 
treatment has the aim to reduce AF occurrence, thromboembolic events and stroke, morbidity and, possibly, 65 
mortality related to this arrhythmia. Apart from the clinical endpoints, achievement of these goals has 66 
economic significance, in terms of positive impact on direct and indirect costs and favorable cost-67 
effectiveness at mid or long term, in the perspective of health care systems (10-12).  68 
In view of the epidemiological profile of AF and progressive aging of the population (13), an 69 
impressive increase of patients at risk of AF or affected by AF (14), also in an asymptomatic stage, is 70 
expected in the next decades, inducing a growing financial burden on health care systems, not only in 71 
Europe and North America, but also worldwide (15, 16).  72 
In consideration of this emerging epidemiological threat due to AF, it is worth considering a 73 
paradigm shift, going beyond the conventional approach of primary prevention based on treatment of AF 74 
risk factors, but, instead, considering the potential for “primordial” prevention, defined as prevention of the 75 
development of risk factors predisposing to AF in the first place (17). This approach, aimed at avoiding the 76 
emergence and penetration of risk factors into the population, has been proposed in general terms for the 77 
prevention of cardiovascular diseases (17) and should imply combined efforts of policymakers, regulatory 78 
and social service agencies, providers, physicians, community leaders, and consumers, in an attempt to 79 
improve social and environmental conditions, as well as individual behaviors, in the pursuit of adopting 80 
healthy lifestyle choices  (16). Since a substantial proportion of incident AF events can be attributable to 81 
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elevated or borderline levels of risk factors for AF (18), this approach could be an effective way to reduce 82 
the financial burden linked to AF epidemiology. In terms of individual behavior and adoption of a “healthy 83 
lifestyle”, it is worth considering that availability of full healthcare coverage (through health insurance or the 84 
health care system) may in some cases facilitate the unwanted risk of reducing, at an individual level, the 85 
motivation to adopt all the preventive measures that are advisable, in line with the complex concept of 86 
“moral hazard effect” (19). Patient education and patient empowerment are the correct strategies for 87 
avoiding this undesirable effect.  88 
 89 
Obesity 90 
Obesity is associated with the development of AF and has an important impact on AF-related clinical 91 
outcomes (Table 1) (20-25). A strategy of weight control may reduce the increasing incidence of AF making 92 
it an important subject in the prevention of AF (20, 26, 27) and long-term benefit for patients at risk for 93 
developing AF (28). The strongest evidence for adverse clinical outcomes comes from various large cohort 94 
studies (Table 1). The Framingham Heart Study (21) revealed that obesity is an important predictor of 95 
development of AF in adults and demonstrated via echocardiographic data, that the relationship between 96 
body size and AF is mediated by left atrial enlargement and inflammation (29) . A recent community-based 97 
study in the Netherlands confirmed that, in addition to the conventional risk factors for AF, body mass index 98 
(BMI) was strongly associated with AF with a 45% increased risk of AF with every 5 points of BMI 99 
increase (22). This study supports the notion that BMI should be regarded as a validated risk factor for 100 
incident AF (22). Indeed, obesity was the strongest contributor to incident AF in a number of studies, 101 
worldwide (22-24, 30).  In the Guangzhou Biobank Cohort Study, for example, both general and central 102 
obesity were associated with increased risk of AF in an Asian population with generally much lower levels 103 
of obesity compared to Western countries (24). 104 
A large Danish prospective population-based cohort study (25), among 55,273 men and women aged 105 
50-64 years of age at recruitment, also confirmed the association between obesity and  incident AF. In 106 
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addition, bioelectrical impedance derived measures of body composition and combinations of 107 
anthropometric measures of body fat distribution were associated with the increased risk of developing AF 108 
(25). Also, diabetes at baseline increased proportionally from 6.9% with a BMI <25 kg/m
2 
to 26% in those 109 
with a BMI >30 kg/m
2 
(25). This is probably important since a meta-analysis has shown that patients with 110 
diabetes had an approximately 40% greater risk of AF compared to those without diabetes (31).  111 
The potential implications of these findings are amplified by the fact that obesity has reached 112 
epidemic proportions worldwide (32). As both AF and obesity are increasing in low and middle income 113 
countries, the results should have significant public health implications. Importantly, obesity may contribute 114 
to the risk of AF-related complications.  For example, another large cohort study from Denmark has shown 115 
that the combination of overweight and AF can increase the risk of stroke and death (33), demonstrating that 116 
being either overweight or obese increases the risk for ischemic stroke, thromboembolism and death in 117 
patients with AF, even after adjustment for the CHADS2 and CHA2DS2-VASc risk scores. However, an 118 
obesity paradox exists. As an example, The Atrial Fibrillation Follow-up Investigation of Rhythm 119 
Management (AFFIRM) study, one of the largest multicenter trials of AF including 4,060 patients, found 120 
that obese patients with AF appear to have better long-term outcomes than non-obese patients (34). 121 
A logical consequence of these studies is that overweight/obese patients should be informed that 122 
there is not only a risk for the commonly known consequences such as diabetes, hypertension, coronary 123 
artery disease and heart failure, but also that there is a greater risk of developing AF and a subsequent risk of 124 
stroke and death. 125 
 126 
 127 
 128 
 129 
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Table 1.  Obesity and risk of AF in population cohorts. Incidences per total duration of follow-up. 
Study Design Subjects FU BMI groups (kg/m
2
) AF,% Risk* (95%CI) 
Dublin et al.
23
 
 
Population 
based,  
case-control 
design 
1,410 cases  
2,203 
controls 
N/A Obese: (BMI ≥30) N/A OR: 1.40 (1.15-1.71) 
Long et al.
24
 Nested  
case-control 
study 
5,882 men 
 
14,548 
women 
N/A Overweight  
(BMI 23-<25) 
Obese (BMI ≥25) 
0.8 Overweight: 
1.18 (0.78–1.79),  
 
Obese: 1.47 (1.01–2.13) 
Tedrow et al.
20 
Women's Health 
Study
 
Prospective 
cohort study  
34,309 12.9±1.9 
yrs 
Overweight (BMI 25-
<30)  
Obese (BMI ≥30) 
2.4 Overweight:  
HR 1.22( 1.02 1.45)  
Obese: 
 HR: 1.65(1.36 - 2.00) 
Wang et al.
21
 
Framingham 
Heart Study 
Prospective 
cohort study 
5,282 13.7 yrs Normal  (BMI 18.5-
<25) 
Overweight (BMI 25-
<30) Obese (BMI≥30) 
10.0 Obese: 
men 1.52 (1.09-2.13) 
women 1.46 (1.03-2.07)  
Frost et al.
25
 Prospective 
cohort study 
55,273 13.5 yrs Underweight (BMI< 
18.5) 
Normal (BMI 18.5-
<25) 
Overweight (BMI 25-
<30) 
Obese (BMI ≥30) 
Men  
3% (1,669) 
Women 
1.6% (912) 
1.29 (1.24-1.33) 
Vermond et al
22
 
 
Dutch 
community 
based cohort 
study 
8,265 9.7 yrs Continuous BMI AF 
incidence 
3.3 per 1000 
person-year 
BMI,  per 5 kg/m2  
HR: 1.45 (1.21–1.74)  
 
*HR per 1 sex-specific standard deviation (SD) or the adjusted HR for 1 sex-specific SD increment 
AF – atrial fibrillation, BMI – body mass index, CI – confidence interval, FU – follow-up, HR – hazard ratio, N/A – not available, 
OR- odds ratio, pts- patients, SD – standard deviation, yrs-years  
 130 
General dietary considerations 131 
There is currently a paucity of evidence on the effect of unhealthy or extreme weight-loss diets on 132 
the development of AF (Table 2) (35-40), and therefore the association between specific dietary factors and 133 
AF is tenuous at this time.  Only one study falls under this topic, by Al Suwaidi et al. (41) which enrolled 134 
465 outpatients who were fasting during the month of Ramadan. Of the approximately 5% who had AF at 135 
enrollment, only one had to be hospital admitted. There were no reports on conversion to or from AF in 136 
other patients.  All other studies refer to specific dietary habits or interventions (42), rather than to extreme 137 
diets. Other data are limited by virtue of selective reporting, multiple testing, and positive publication bias. 138 
Also, many studies are small, some are retrospective and the effect sizes of dietary exposures are modest 139 
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leading to potential residual confounding, especially since diet is inextricably linked with age, race, sex, 140 
socioeconomic status, etc.  141 
 142 
Table 2. Relation between diet and AF 
Study Design Subjects FU Intervention AF risk (95%CI) Comment 
(a) Population cohorts 
Shen  et al.35 
Framingham Heart 
Study  
Prospective  4,526 from 
original and 
off-spring 
cohort; 
participants 
without AF 
4 yrs None No association with 
alcohol, caffeine, 
fiber and fish-derived 
polyunsaturated fatty 
acids; limited 
attributable risk of 
AF>4 servings of 
dark fish/wk had  
HR 6.53 (2.65-16.06) 
vs. <1 serving 
Alcohol, caffeine, fiber, and fish-
derived polyunsaturated fatty 
acids were not associated with AF 
risk 
 
Khawaja et al.36 
Physicians‟ Health 
Study  
Prospective 21,054 men 20 yrs 
(median 
24 yrs) 
None - No association between nut 
consumption and incident AF 
Fretts et al37 
Cardiovascular Health 
Study  
Prospective  4,337 
>65 yrs; no 
prevalent 
CHD or AF 
up to 19 
yrs 
None - No association between plasma 
phospholipid or dietary alpha 
linoleic acid and incident AF 
Costanzo  et al.38 Prospective 217; cardiac 
surgery 
ICU 
stay + 1 
wk post 
surgery 
unit 
None Highest tertile of 
dietary total 
antioxidant capacity 
vs. 2 lowest tertiles:  
OR 0.46 ( 0.22-0.95) 
Antioxidant-rich foods are 
associated with reduced incidence 
of postoperative AF   
 
 
Mattioli et al.39 Case-control  800; 400 
first 
detected AF 
episode 
- None  
a) OR 1.9 (1.58-2.81) 
 
 
 
b) OR 1.8 (1.56-2.99)  
a) Lower adherence to 
Mediterranean diet and lower 
antioxidant intake in patients with 
AF compared to control 
population; 
b)  Patients with arrhythmia who 
had higher Mediterranean 
score had higher probability of 
spontaneous conversion from AF 
to sinus rhythm 
Pastori et al.40 Prospective  709 
anticoagula-
ted pts with 
AF  
39.9 
months 
None - Reduction in CV events; 
antioxidant effects such as down-
regulation of NOX2 and 
decreased excretion of F2-
isoprostanes 
(b)Intervention studies 
Martínez-González  et 
al.42 
PREDIMED- 
Prevención con Dieta 
Mediterránea  
Randomized 
primary 
prevention 
trial; post-
hoc analysis 
6,705 Median 
4.7 yrs  
3 diets: 
Mediterranean 
diet enriched 
with extra virgin 
olive oil or 
mixed nuts; 
control group 
Mediterranean diet  
enriched with extra 
virgin olive oil vs 
mixed nuts; 
 
HR 0.89 (0.65-1.2) 
 
Mediterranean diet  
enriched with extra 
virgin olive oil vs 
control group:  
 
HR 0.62 (0.45-0.85) 
Mediterranean diet with olive oil 
reduced AF risk compared with 
control group, however with no 
effect in a group with nuts 
Reduced incidence of stroke, 
myocardial infarction, and CV 
mortality; consumption of extra 
virgin olive oil but not nuts was 
associated with a lower risk of AF 
AF – atrial fibrillation, CHD – coronary heart disease, CI – confidence interval, CV- cardiovascular, FU – follow-up, HR – hazard ratio, ICU – 
intensive care unit, OR- odds ratio, pts-patients, wk-week, yrs-years 
 143 
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Blood lipids and fish consumption 144 
Among the modifiable risk factors that can be targeted for AF prevention, caloric intake and physical 145 
activity are critical factors that significantly impact weight, blood pressure, risk of diabetes mellitus and 146 
atherosclerosis, and atrial structure/function (43).  147 
What is the impact of blood lipids on risk of AF?   148 
Table 3A summarizes two recent cohort-based studies that evaluated the association of blood lipid 149 
components with the development of AF during follow-up (44, 45). In both, with adjustments for age, sex, 150 
and race, but no adjustment for BMI, low levels of HDL cholesterol and high levels of plasma triglycerides 151 
were associated with increased risk of AF. Low-density lipoprotein cholesterol levels (LDL) were not 152 
associated with AF risk in either study; elevated total cholesterol was associated with risk of AF in one study 153 
(44). Both studies note the impact of comorbid conditions confounding the association of blood lipid levels 154 
with AF risk. Thus, evidence for selectively targeting lower plasma LDL or total cholesterol as a means of 155 
reducing AF risk is weak.       156 
Despite the uncertain association of lipids with incident AF, there is evidence that statins protect 157 
against AF in patients with chronic stable coronary artery disease, independently of reductions in plasma 158 
total cholesterol level (46). In experimental studies, statin use protected against electrical remodeling 159 
associated with atrial tachycardia pacing (47) and decreased AF inducibility in a canine model of sterile 160 
pericarditis (48). Recent meta-analyses suggest that statins reduce new onset AF following cardiac surgery, a 161 
setting in which inflammatory processes are strongly implicated in AF onset (49, 50).  In contrast to the 162 
post-surgical setting, large meta-analyses have not demonstrated the efficacy of statins for primary 163 
prevention of AF, whilst a heterogeneous benefit is reported for secondary AF prevention (51, 52).  Statins, 164 
which impact oxidant and inflammatory mechanisms in addition to lowering plasma LDL levels, most likely 165 
attenuate AF risk primarily due to effects independent of LDL reduction.   166 
In recognition of this “uncoupling,” recent ACC/AHA guidelines for prevention of coronary heart 167 
disease have changed from a primary focus on specific LDL target levels to one that focuses on the overall 168 
risk factor profile of the patient (53). A similar logic may apply to AF prevention as well. 169 
 170 
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Dietary fish consumption vs. studies with fish oil supplements 171 
Older epidemiologic studies have suggested that consumption of fatty fish is associated with 172 
significant health benefits, including reduced risk of AF (54). One recent study in the USA (Table 3B) noted 173 
a non-significant trend for a lower incidence of AF with higher intake of fatty fish (p=0.09) (55). Fish oil is 174 
enriched in omega-3 polyunsaturated fatty acids (3-PUFA), especially eicosapentaenoic acid (EPA) and 175 
docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA). The Kuopio Study found a trend for the 176 
highest vs. lowest quartile of plasma EPA+DHA+DPA to be associated with lower risk of AF (p=0.07). This 177 
relationship was modestly significant for DHA (p=0.02) (56). A retrospective analysis of a large Danish 178 
cohort (n=55,246), which was  a population with high fish consumption, suggests that the relationship 179 
between fish consumption and AF risk is more complex and U-shaped, with both low- and high-levels of 180 
either fatty fish consumption or consumption of the individual omega-3-fatty acids associated with increased 181 
risk of AF (57).  Also, in the Danish population  (Table 3B), analysis of adipose DHA and EPA content 182 
identified non-significant trends for benefit with elevated levels of both DHA and EPA (58). An obvious and 183 
important confounding factor is the individual burden of adiposity.   184 
While fish oil extracts have demonstrated significant effects on the development of atrial fibrosis in 185 
the setting of experimental heart failure (59), and on the inducibility of AF after experimental cardiac 186 
surgery (60), highly purified n3-PUFA supplements, often formulated as ethyl esters, have demonstrated 187 
either poor or no efficacy in randomized clinical trials for the prevention of new onset AF following cardiac 188 
surgery (61), or for prevention of AF recurrence (62, 63) It remains unclear if the lack of efficacy is related 189 
to differences in bioavailability (64), to loss of other components in fish that are functionally important, or to 190 
intrinsic differences between studies in younger experimental animals and those in older patients at greatest 191 
risk of AF. At present, there is no compelling argument for the use of commercially available fish oil 192 
supplements for either primary or secondary AF prevention (65, 66). 193 
On the basis of the available epidemiologic studies, the current AHA/ACC guidelines for individuals 194 
with elevated blood LDL levels now recommends consumption of a diet “that emphasizes intake of 195 
vegetables, fruits, and whole grains; includes low-fat dairy products, poultry, fish, legumes, non-tropical 196 
vegetable oils, and nuts; and limits intake of sweets, sugar-sweetened beverages, and red meats” (66).  197 
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While quite reasonable, this and other similar guidelines do not specifically address diet in relation to 198 
AF risk. Lacking direct evidence, the above dietary suggestions coupled with an emphasis on physical 199 
activity and maintenance of a healthy lifestyle and weight seem reasonable as interim guidance for AF 200 
patients, and for those with significant risk of AF.   201 
 202 
Table 3. Relationship of blood lipids, fish and n-3 polyunsaturated fatty acids to incident AF risk per 
total duration of follow-up. 
 
Study Design Subjects FU, 
yrs 
LDL/ HDL, TG, TC levels AF, 
n(%) 
Risk 
HR (95% CI), p-value 
(a) Blood lipids 
Lopez et al.44 
ARIC 
Community 
cohort study; 
baseline age – 
45-64 yrs 
13,969 18.7  
 
 
 
HDL 60 mg/dL, vs. 40 mg/dL 
TC >240 mg/dL vs. <200 mg/dL 
TGs 200 mg/dL vs. 150 mg/dL 
LDL (not significant) 
1,433 
(10.25) 
 
 
0.63 (0.53-0.74),* p<0.0001  
0.89 (0.77-1.02), p=0.03  
1.4 (1.21-1.62), p<0.0001 
Alonso et al.45 
MESA 
Framingham Heart 
Study 
Community 
cohorts;  
average baseline 
age 60.5 yrs (10) 
7,142 9.6  
 
 
HDL 60 mg/dL, vs. 40 mg/dL 
TGs 200 mg/dL vs. 150 mg/dL 
TC, LDL not significant 
480 
(6.7) 
 
0.64 (0.48-0.87) 
1.6 (1.25, 2.05) 
 (b) Fish intake and plasma n-3 fatty acid levels 
Gronroos et al.55 
ARIC 
Community 
cohort study, 
baseline age 45-
64 yrs 
14,222 17.6  
 
 
 
Intake of canned tuna/oily fish > 
2/week, vs. none 
 
Dietary DHA+EPA (Q4 vs. Q1) 
Plasma DHA+EPA (Q4 vs. Q1) 
Plasma DHA (Q4 vs. Q1) 
Plasma EPA (Q4 vs. Q1) 
1,604 
(11.3) 
 
 
0.86 (0.72-1.03), p=0.09 
 
 
0.95 (0.82-1.10)*, p=0.42 
0.79 (0.60, 1.03), p=0.18 
0.74 (0.57, 0.97), p=0.10 
1.12 (0.85, 1.49), p=0.33 
Rix et al.57 
Danish Diet, 
Cancer and Health 
cohort study 
Cohort study, 
baseline ages 
50-64 yrs  
57,053 13.6  
 
 
Dietary intake: 
Q1 (<0.39 g/day) 
Q2 vs. Q1  
Q3 vs. Q1 
Q4 vs. Q1 
Q5 vs. Q1 
3,345 
(5.9) 
 
 
1 
0.92 (0.82-1.03), p=0.16 
0.87 (0.78-0.98), p=0.02 
0.96 (0.86-1.08), p=0.49 
1.05 (0.93-1.18), p=0.42 
Rix et al.58 
Danish Diet, 
Cancer and Health 
cohort study 
Cohort study, 
baseline ages 
50-64 yrs 
3,440 with 
adipose 
tissue 
specimens 
13.6  
 
 
Total adipose n3-PUFA 
  T2 vs. T1 
  T3 vs. T1 
 
Adipose DHA 
  T2 vs. T1 
  T3 vs. T1 
 
Adipose EPA 
  T2 vs. T1 
  T3 vs. T1 
179 
(5.2) 
 
 
0.87 (0.60-1.24) 
0.77 (0.53-1.1) 
 
 
1.03 (0.73-1.46) 
0.73 (0.5-1.06) 
 
 
0.67 (0.46-0.99) 
0.86 (0.61-1.22) 
Virtanen et al.56 
Kuopio Ischemic 
Heart Disease Risk 
Factor Study  
Cohort study, 
baseline ages 
42-60 years 
1,941 with 
serum 
specimens 
17.7  
Plasma DHA+EPA+DPA 
Q2 vs. Q1 
Q3 vs. Q1 
Q4 vs. Q1  
 
Plasma DHA (Q4 vs. Q1) 
Plasma EPA (Q4 vs. Q1) 
240 
(11.0) 
 
 
0.65 (0.46-0.93) 
0.82 (0.58-1.14) 
0.65 (0.46-0.93) 
 
0.64 (0.45-0.92) 
0.93 (0.0.65-1.33) 
*corrected only for age, sex, race 
AF – atrial fibrillation, CI – confidence interval, DHA - docosahexaenoic acid, FU – follow-up, HDL – high-density lipoprotein cholesterol, HR – hazard ratio, EPA - 
eicosapentaenoic acid, LDL – low-density lipoprotein cholesterol, n3-PUFA -omega-3 polyunsaturated fatty acids, Q-quartile, T- tertile, TC- total cholesterol, TG- 
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triglyceride, yrs- years  
 203 
 204 
Obstructive sleep apnea 205 
Sleep related breathing disorders are common and approximately 25% of adults are at risk for sleep 206 
apnea of some degree (67), with obstructive sleep apnea (OSA) commonly seen in patients with 207 
cardiovascular diseases, especially in obese patients and those with type 2 diabetes mellitus (68). Various 208 
studies have established that patients with OSA, particularly those with more severe disease, are 209 
significantly more likely to develop AF, and patients with AF have about twice the risk for developing OSA 210 
(Table 4) (69, 70). 211 
Patients with AF and those with OSA share several similar characteristics.  For example, 212 
hypertension is common (one third of OSA) in both conditions, and both occur more frequently in men and 213 
increase with advancing age (68). Furthermore, increasing BMI plays an important role in development of 214 
both obstructive sleep apnea and AF (28, 71).  215 
The mechanisms for this may be multifactorial, but autonomic dysregulation may connect sleep 216 
apnea and AF, independent of other known risk factors. This has been confirmed experimentally in dogs 217 
(72) and clinically (73). In a prospective cohort study (73), a relationship among the severity of sleep apnea 218 
syndrome, cardiac arrhythmias, and autonomic imbalance was demonstrated. 219 
These observations may have important clinical implications, and large observational studies suggest 220 
that OSA may be a modifiable risk factor for recurrent AF after cardioversion or ablation (74, 75). 221 
Furthermore, some data support a role for continued positive airway pressure (CPAP) therapy in abolishing 222 
nocturnal ventricular asystole and improving other arrhythmias in patients with obstructive sleep apnea (76-223 
78, 79).  CPAP therapy was effective in several other studies (80-83), but not in heart failure patients (84).  224 
Based on the evidence, routine screening for OSA and other sleep related breathing disorders in 225 
general practice and in cardiac rehabilitation programs may be considered if clinically indicated. More data 226 
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are needed to show the benefit of prevention and treatment of OSA and associated improvement of AF 227 
incidence, recurrence rate and outcomes in patients with new onset or recurrent AF. 228 
 229 
Table 4. Incident risk of AF in obstructive sleep apnea per total duration of follow-up. 
Study Design Subjects FU, yrs OSA, n (%) AF,% Risk (95%CI) 
Gami et al.
69
 
 
Olmsted 
County 
cohort study 
3,542 4.7 2626 (74) 14.0 HR 2.18 (1.34- 3.54) 
       
Cadby et al.
70
 
 
Sleep-clinic 
cohort study 
6,841 11.9 100% 6.7 HR 1.55 (1.21- 2.00) 
AF – atrial fibrillation, CI – confidence interval, FU – follow-up, HR – hazard ratio,  OSA- obstructive sleep apnea, pts- 
patients, yrs – years 
 230 
 231 
Hypertension 232 
 Hypertension is a major risk factor for AF (Table 5). In the Framingham Heart Study (85) the odds 233 
ratios for the development of AF in men and women with hypertension were 1.5 and 1.4, respectively. Data 234 
from the Atherosclerotic Risk in Communities Study (18) show that approximately one fifth of the risk of 235 
developing AF was attributable to hypertension.  The optimal systolic blood pressure appears to be 120-130 236 
mm Hg with both higher and lower blood pressures associated with an increased incidence of AF (22, 86, 237 
87). 238 
Proposed mechanisms include sympathetic activation, activation of the renin-angiotensin-aldosterone 239 
system, atrial dilation, fibrosis and left ventricular remodeling including diastolic dysfunction and left 240 
ventricular hypertrophy (43).  Hypertension may also lead to coronary disease and myocardial infarction, 241 
subsequently increasing the risk for AF.  Alcohol consumption is also a common predisposing factor to both 242 
AF and hypertension. 243 
 For the primary prevention of AF in a hypertensive population, the optimal on-treatment systolic BP 244 
goal appears to be <130 mmHg (88).   Nevertheless, it remains unclear whether different antihypertensive 245 
medications affect the development of AF independent of blood pressure reduction.  In the Losartan 246 
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Intervention for End Point Reduction in Hypertension Study (89), for example, new onset AF occurred less 247 
frequently in patients treated with losartan compared to patients treated with atenolol, although blood 248 
pressure reduction was similar in both groups.  In another study (90), ACE inhibitors and angiotensin II-249 
receptor blocker (ARB) were superior to beta-blockers and diuretics for the primary prevention of AF. These 250 
two studies suggest that the inhibition of the renin-angiotensin system may be associated with a decreased 251 
risk of new onset AF, incremental to the effect of BP reduction alone.  252 
 ARB therapy has also been studied for the secondary prevention of AF. For example, the GISSI-AF 253 
study (91) evaluated the secondary prevention of AF using valsartan, but was not superior to placebo. 254 
Follow-up was only for one year and it remains possible that the beneficial effects of ARBs on atrial 255 
remodeling might be seen with a longer study duration (92). In the ANTIPAF trial (93), olmesartan did not 256 
decrease AF burden compared to placebo in patients without structural heart disease. 257 
 Additionally, Lip and colleagues (94), retrospectively analyzing data from the SPORTIF III and 258 
SPORTIF V trials, found that ACEI and ARBs did not result in any difference in stroke or systemic 259 
embolism in a controlled, anticoagulated AF population. Mortality was lower in the AF population over 75 260 
years of age treated with ACEI or ARBs.  261 
The role of aldosterone antagonists in the treatment of AF has been evaluated in the setting of heart 262 
failure (95), but not in its absence. Given the increasing incidence of AF, additional well-conducted studies 263 
are needed to clarify the impact of renin-angiotensin-aldosterone system (RAAS) inhibitors on both the 264 
primary and secondary prevention of AF (8, 96). 265 
 266 
Table 5. Hypertension and risk of AF 
Study Design Subjects FU BP levels, 
mmHg/ 
Treatment  
AF Risk (95% CI) 
AF Incidence Trials 
Benjamin et 
al.
85
 
Framingham 
Heart Study  
Cohort 2,090 men 
2,641 
women 
38 yrs SBP > 160  
DBP > 95 
 OR  for AF 
Men 1.5 (1.2-2.0) 
Women 1.4 (1.1-1.8) 
Huxley et al.
18
 
ARIC Study 
Cohort 14,598 17.1 yrs SBP > 140  
DBP > 90 
 21.6% (16.8-26.7) of 
risk of AF is 
attributable to HT 
Thomas et al.
86
 Case - Control 433 pts 
with AF 
899 
20 yrs  
(median) 
SBP < 120 
120-129 
130-139 
 OR 1.99 (1.10-3.62) 
Reference 
1.19 (0.78-1.81) 
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Controls 
 
140-149 
150-159 
160-169 
>170 
1.40 (0.93-2.09) 
2.02 (1.30-3.15)  
2.27 (1.31-3.93)  
1.84 (0.89-3.80) 
Vermond et 
al.
22 
 
Dutch 
community 
based cohort 
study 
8,265 9.7 yrs Per 10 mm SBP AF 
incidence 
3.3 per 
1000 
person-
year 
SBP,  per 10 mm Hg 
HR 1.11 (1.01–1.22)  
 
Intervention Trials 
Primary Prevention 
Wachtell et al.
89 
 
LIFE Study  
Randomized, 
double blind 
comparison of 
losartan vs. 
atenolol 
Losartan 
4,298 
Atenolol 
4,182 
4.8 yrs 
(mean) 
Losartan 
Atenolol 
New AF 
150  
New AF 
221  
RR 0.67 (0.55-0.83) 
Marott er al.
90
 Registry 
analysis: 
Comparison of 
AF incidence in 
pts with HT 
treated with 
ACEI and ARB 
compared to 
BB, diuretics 
and CCB 
725,680 
Danish pts 
treated with 
anti-HT 
monotherap
y 
5.9 – 6.8 
yrs 
 
depending 
on 
compariso
n 
ACEI vs BB  
ARB vs BB  
ACEI vs 
diuretic 
ARB vs diuretic 
ACEI vs CCB  
ARB vs CCB   
 0.12 (0.10-0.15) 
0.10 (0.07- 0.14) 
0.51 (0.44-0.59) 
0.43 (0.32- 0.58) 
0.97(0.81- 1.16) 
0.78 (0.56- 1.08) 
   
Okin et al.
88
 Analysis of the 
effect of BP 
reduction using 
losartan or 
atenolol 
(randomly 
assigned) on the 
risk of new AF 
8831patients 
with HT, 
ECG 
evidence of 
LVH and no 
history of 
AF  
4.6 yrs  SBP  < 130 
 
SBP 131-141 
 
SBP > 142 
Overall 
new AF in 
701 pts 
(7.9%) 
Compared to SBP > 
142, SBP < 130 is 
associated with 40% 
lower risk of AF 
(18%-55%). 
 
Compared to SBP > 
 131-141, SBP < 130 
is associated with 
24% lower risk of AF  
(7%-38%). 
Secondary Prevention 
GISSI-AF
91
 Randomized 
double blind 
comparison of 
valsartan vs 
placebo for 
prevention of 
recurrent AF 
1,442 pts 
Valsartan 
722 
Placebo 720 
1 year Valsartan  
 
 
Placebo 
Recurrent 
AF 371 
(51.4%) 
  
Recurrent 
AF 
375 
(52.1%)  
HR 0.97 (0.83-1.14) 
ANTIPAF
93
 Randomized 
double blind 
comparison of 
olmesartan vs 
placebo for 
prevention of 
recurrent AF 
burden 
425 pts w/o 
structural 
heart 
disease. 
Approx. 
49% with 
htn 
12 months Olmesartan 
 
 
Placebo 
% of AF 
days 
15.1%  
 
% of AF 
days 
14.7% 
No difference 
(p=0.77) 
 Page 19 of 82 
Lip et al.
94
 Retrospective 
longitudinal 
analysis of 
participants in 
SPORTIF III and 
V trials. 
Comparison of  
clinical event 
rates and 
mortality in ACEI 
and ARB users 
compared to non-
users in an anti-
coagulated AF 
population 
4,760 ACEI 
or ARB 
users 
2,569 ACEI 
or ARB non-
users 
18.7 
months 
ACEI 
ARB 
 users 
18.4 
months 
ACEI 
ARB  
non-users 
 
ACEI-ARB 
users 
 
ACEI-ARB 
non- 
users 
 
 
 
 No difference in 
stroke, systemic 
embolic event, or 
mortality in ACEI, 
ARB users compared 
to non-users in the 
entire cohort 
For age > 75 years 
lower mortality in 
ACEI or ARB users 
compared to non-
users: 
 HR 0.71 (0.52-0.95)  
 
ACEI – angiotensin-converting enzyme inhibitor, AF – atrial fibrillation, ARB – angiotensin receptor blocker, BB – beta-
blocker, BP – blood pressure, CCB- calcium channel blocker, CI – confidence interval, DBP – diastolic blood pressure, FU – 
follow-up, HR – hazard ratio, HT – hypertension, OR – odds ratio, pts- patients, RR – relative risk, SBP – systolic blood 
pressure, yrs – years 
 267 
 268 
 269 
 270 
Diabetes Mellitus 271 
 Diabetes and elevated blood glucose have been recognized for several years as potential risk factors 272 
for AF, although there are conflicting results (97) (Table 6). Multiple studies (31, 85, 98-104) report an 273 
increased incidence of AF in patients with diabetes. However, there are methodological differences that 274 
make comparisons among studies difficult. In particular, some studies adjusted the results for confounding 275 
variables including obesity and hypertension, while others did not. When these other risk factors were 276 
considered, the risk attributable to the development of AF from diabetes was limited. In a meta-analysis of 277 
seven cohort studies and 4 case control studies including more than 1,600,000 subjects, Huxley et al. (31) 278 
found that patients with diabetes had a 39% greater risk of developing AF compared to individuals without 279 
diabetes. In studies that adjusted the risk for confounding variables, the relative risk decreased to 1.24 (95% 280 
CI 1.06 to 1.44). 281 
Using a population based, case-control design, Dublin et al. (104) found that patients with longer 282 
durations of diabetes had a greater risk of AF development. Specifically, the risk of AF was 3% higher for 283 
each year of diabetes treatment, and the risk of AF correlated with worsened glycemic control. Hence, better 284 
glycemic control (as measured by hemoglobin A1c) was associated with a lower risk of AF development. 285 
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High basal hemoglobin A1c level, increased body mass index and advanced age were also associated with 286 
higher recurrence of AF after catheter ablation in patients with diabetes (105).  287 
 Recently, investigators using the Taiwan National Health Insurance Research Database developed a 288 
time-dependent Cox proportional hazard model to study the effects of metformin on the development of AF 289 
(106). The study population included 645,710 patients with diabetes taking metformin but not other diabetic 290 
medications. Over a 13-year follow-up, fewer patients taking metformin developed AF, suggesting that 291 
metformin had a protective effect on the development of AF in diabetic patients. 292 
Additionally, the duration of diabetes appears to be related to a higher risk of thromboembolic events 293 
in patients with AF. Using data from multiple Danish registries, Overvad et al. (107) identified 13,722 294 
patients with AF, 12.4% of whom had diabetes. Compared to AF patients without diabetes, 295 
thromboembolism was more prevalent and this relationship was time-dependent with longer diabetes 296 
duration being associated with higher rates of thromboembolism and death. A longer diabetes duration was 297 
not associated with an increased risk of bleeding among AF patients treated with vitamin K antagonists. 298 
 In summary, diabetes appears to confer an increased risk for the development of AF, but this risk 299 
seems less than for other factors including hypertension, obesity and smoking (18). Furthermore, a longer 300 
diabetes duration and worse glycemic control increases the risk for AF and its complications, and in one 301 
retrospective study (106), treatment with metformin appeared to reduce this risk.  302 
 303 
Table 6. Diabetes and risk of AF 
Study Design Subjects FU FBG or HbA1c 
levels/DM 
duration 
AF Risk (95% CI) 
Incidence 
Benjamin et al. 85 
Framingham 
Heart Study 
Cohort 2,090 men 
2,641 women 
38 yrs FBG >140 mg/dl 
Non-fasting BG 
>200 mg/dl 
 OR  for AF 
Men 1.4 (1.0-2.0) 
Women 1.6 (1.1- 2.2) 
 
After adjustment for valve 
disease 
Men 1.1 (0.8- 1.7) 
Women 1.5 (1.0- 2.3) 
Alonso et al.98 
 
Meta-
analysis of 
3 cohorts: 
ARIC, 
CVH and 
FHS 
18,556 pts    HR 1.27 (1.10, 1.46) for 5- year 
AF risk in pts with DM 
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Huxley et al.99  
ARIC Study 
Cohort 13,025 14.5 yrs FBG > 126 mg/dl 
or HbA1c > 6.5% 
or use of diabetic 
meds 
 Diabetes is associated with 
increased incidence of AF:  
HR 1.35 (1.14-1.60) 
 
HbA1c levels are independently 
associated with AF: HR 
1.13(1.01-1.20) per 1% increase 
in HbA1c level 
Ostgren et al.100 Cohort  171 HT + DM      
147 DM only    
597 HT only     
825 no HT or 
DM     
FBG > 6.6 
mmol/l or 
2hr glucose after 
oral glucose 
tolerance test > 
11.0 mmol/l 
 HT + DM: OR 3.3 (1.6-6.7)                
DM only: OR 2.0 (0.9-4.7)                     
HT only: OR 0.7 (0.3-1.5)                            
Reference no HT or DM: ORR 
1.0 
Pfister et al.101 Analysis of 
developmen
t of new AF 
in the 
PROactive 
trial 
5233 pt with 
DM 
 
36 months   Incidence of new AF at:                                      
12 months -  0.8%                                           
24 months -  1.5%                                        
36months –  2.4% 
 
Schoen et al.102              
Womens Health 
Study 
Cohort 34,720 women 
health 
professionals 
16.4 years  At baseline 
937 
(2.75%) had 
DM 
Compared to women without 
DM, women with DM had HR 
for new AF of 1.95 (1.49-2.56). 
In models that adjusted for HT, 
obesity (BMI) and inter-current 
cardiovascular events, HR for 
new AF decreased to 1.14 (0.93-
1.40) 
Dublin et al.104 Case- 
control 
1,410 new AF  
pts 
2,203 control 
pts 
21 yrs - 
AF pts 
20 yrs - 
control pts 
 
 
 
 
 
 
HbA1c <7% 
HbA1c 7-8%  
HbA1c 8-9% 
HbA1c > 9% 
252 
(17.9%) AF 
pts had DM 
 
311 
(14.1%) 
control pts 
had DM  
OR for AF 1.40 (1.15-1.71) for 
pts with DM compared to those 
without DM 
 
Compared to pts without DM 
risk (OR): 
 
1.06 (0.74-1.51) 
1.48 (1.09-2.01) 
1.46 (1.02-2.08) 
1.96 (1.22-3.14) 
Aksnes et al. 103 
VALUE Trial  
Prospective 
randomized 
trial 
comparing 
valsartan 
and 
amlodipine 
for 
treatment of 
htn  
15,245 total pts 
with  htn 
5,250 diabetes 
at baseline 
1,298 developed 
diabetes during 
FU 
4.2 yrs FBG >140 mg/dl  551 pts 
developed 
AF during 
the trial 
HR 1.49 (1.14, 1.94) new onset 
diabetes for development of AF 
HR 1.19 (0.99, 1.42) baseline 
diabetes for development of AF 
Huxley et al. 31 Meta-
analysis of 
cohort (7) 
and case 
control (4) 
studies. 
1,686,097 
subjects 
combined 
allstudies 
   RR of pts with DM for AF: 1.39 
(1.10 – 1.75) 
Studies with adjustment for other 
risk factors, RR of pts with DM 
for AF: 1.24 (1.06 – 1.44) 
Intervention Trials 
Chang et al.106 Registry 645,710 pts with 
diabetes 
13 yrs  9983 pts 
developed 
AF, 
incidence 
rate 1.5% 
(287/10000
0 
person/yrs) 
Metformin use protected against 
the development of AF,  
HR 0.81 (0.76- 0.86) 
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Overvad et al.107 Registry 137,222 pts with 
AF 
 
  
No DM 120204 
DM 0-4 yrs 7922 
DM 5-9 yrs 4781 
DM 10-14 yrs 
2435 
DM > 15 yrs 
1880 
 Risk of thromboembolism or 
death 
No DM Reference 1.0 
HR 1.24 (1.20-1.29) 
HR 1.42 (1.37-1.48) 
HR 1.45 (1.37-1.53) 
HR 1.72 (1.62-1.82) 
ARIC - Atherosclerotic Risk in Communities, CVH -Cardiovascular Health Study, FHS - Framingham Heart Study, VALUE -Valsartan 
Anti-hypertensive Long-term Use Evaluation Trial 
AF – atrial fibrillation, BG- blood glucose, BMI – body mass index, DM – diabetes mellitus, FBG – fasting blood glucose, FU – follow-up, 
HbA1c – glycated hemoglobin, HR – hazard ratio,  HT – hypertension, OR – odds ratio,  pts- patients, yrs- years 
 304 
 305 
Smoking 306 
Smoking is reported to predict incident AF in individuals of European (98, 108-111), African, (108, 307 
112) and Japanese (113) ancestry (Table 7). Risks of developing incident AF with smoking are similar in 308 
men and women (98, 108-114), and in blacks and whites (108). Multivariable risk prediction models for AF 309 
indicate that compared to nonsmokers, both current (109, 110) and ever smokers (110) have a higher risk of 310 
incident AF. Current smoking was responsible for about 10% of the variability in AF risk (18). Some data 311 
also suggest a dose response relationship, with the highest risk of AF observed in individuals with the 312 
greatest cigarette-years of smoking (108) and current smokers with increasing number of cigarettes per day 313 
(114). However, not all studies have reported an adjusted association between smoking and AF (2, 30, 115-314 
119), but the lack of association has been ascribed to several factors including modest numbers of cases of 315 
AF, combining current and former smokers (120), adjusting for factors along the causal pathway such as 316 
myocardial infarction, heart failure, and lung disease (114) and competing risks of death among smokers 317 
(108, 120). 318 
Whether other forms of tobacco exposure are associated with AF is more equivocal.  One case report 319 
of an elderly woman with several comorbidities, suggests a possible temporal relation between electronic 320 
cigarettes and paroxysms of AF (121). To our knowledge, there is no published research linking electronic 321 
cigarettes with AF. Similarly, there are no prospective data regarding the relation of secondhand smoke to 322 
AF. However, one recent retrospective study suggested that being exposed to second hand smoke 323 
gestationally or living with a smoker during childhood were associated with an increased risk of AF as an 324 
adult (122). There have also been case reports of AF associated with chewing nicotine gum (123-125). In 325 
contrast, a pooled analysis of Swedish studies found current use of snus, a powdered smokeless tobacco 326 
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product, was not significantly associated with incident AF (RR, 1.07; 0.97-1.19) (126). Whether nicotine per 327 
se, or other chemicals associated with smoking are responsible for the increased risk of tobacco is uncertain.  328 
Both experimental and human studies support multiple mechanisms linking smoking to AF. Nicotine 329 
and cigarettes predispose to inflammation (127), atrial electrical alterations (128, 129), atrial fibrosis (130-330 
132), reduced lung function (133, 134), myocardial infarction (108), and heart failure (108), all of which 331 
predispose to AF. Smoking also may be a marker of deprivation and unhealthy lifestyle (135, 136). An 332 
inverse association between socioeconomic status and incident AF has been reported, which is partially 333 
mediated by other risk factors (137, 138). 334 
 In individuals with AF, most studies examining the risk of events such as stroke, dementia, heart 335 
failure, myocardial infarction (5, 6) and death have included smoking as a covariate, but have not 336 
specifically identified risk factors for events (139). Smoking was not a risk factor for incident heart failure in 337 
individuals with AF (140, 141). Neither the CHADS2 nor the CHA2DS2-VASc scores include smoking as a 338 
risk factor for stroke. However, smoking is a risk factor for stroke in AF, even accounting for coexisting risk 339 
factors (142, 143), but this relationship was  not evident in one study (144). Smoking has also been reported 340 
to predict an increased risk for intracranial bleeding, mortality (143, 145) and the combined outcome of 341 
stroke or death (144) in people with AF. 342 
Although there are no randomized trials proving that smoking cessation reduces the risk of AF, the 343 
preponderance of evidence supports efforts to encourage individuals to avoid uptake or to quit smoking to 344 
reduce their risk. Mirroring population trends, smoking rates in individuals with AF have declined 345 
significantly over time (14). Current smoking was more strongly and consistently associated with AF 346 
compared to former smoking status in most (98, 113), but not all (114) studies (Table 7). In models 347 
excluding individuals with prior coronary heart disease and heart failure, former smoking was no longer 348 
significantly associated with incident AF (98). One biracial observational study noted a nonsignificant trend 349 
towards reduced rates of AF in individuals who had quit smoking (98).  350 
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The results of smoking cessation interventions in AF have not been well studied. Despite the 351 
potential benefits of smoking cessation in AF, individuals with AF were less likely to be prescribed smoking 352 
cessation aids than those without AF (146).  One randomized trial of aggressive risk factor reduction, which 353 
included smoking cessation in individuals post AF catheter ablation, demonstrated that those randomized to 354 
risk factor reduction had lowered AF frequency, duration and symptoms (147).  355 
Table 7. Smoking and risk of AF 
Study Design Subjects FU Tobacco  AF, % Multivariable Risk (95%CI) 
(a) Population cohorts 
Alonso et al. 98 
CHARGE-AF Study 
Meta-analysis 
 3 cohorts,  
 
replication 
 2 cohorts 
 
18,556 
 B & W; 
1186 
incident AF 
7,672 W; 
585 incident 
AF 
5 yrs Current smoking  HR 1.44 (1.20- 1.72) 
Chamberlain et al. 
108 
ARIC 
Cohort 
Incident AF 
15,329 
 B&W 
876 incident 
AF 
Mean  
13.1 yrs 
 
 
Smoking status 
Never 
Ever  
Former 
Current 
Cigarette-yrs. 
0 
≤300 
>300 to ≤675 
>675 
Continued vs. 
quit smoking 
Age-sex adjust. incidence 
rate/10,000 py 
 
28 
41 
36 
48 
 
28 
28 
41 
55 
 
 
 
Reference 
1.58 (1.35-1.85) 
1.32 (1.10-1.57 ) 
2.05 (1.71-2.47) 
 
Reference 
1.04 (0.83-1.30) 
1.60 (1.30–1.95) 
2.10 (1.74–2.53) 
 
0.88 (0.65-1.17) 
Pfister et al.109 
EPIC Norfolk 
Cohort 
Incident AF 
24,020  
W 
236 incident 
hospitalized 
AF 
5 yrs Current smoking  
Incident AF No 
Incident AF Yes 
 
11.6% 
14.0% 
 
1.86 (1.28- 2.69) 
 
Observed in EPIC cohort free of CVD, 
HT, DM: HR 2.03 (1.26, 3.27) 
Friberg et al.110 
Copenhagen City 
Heart Study 
Cohort  
Incident AF 
10,955 
W 
379 incident 
hospitalized 
AF 
7 yrs  
Never smokers 
Current smoking  
Current or ex 
 
NA 
Multivariable-adjusted 
Reference 
2.0 (1.4–2.8) 
1.8 (1.3–2.5) 
Everett et al.111 
Women‟s Health 
Study 
Cohort 
Incident AF 
20,822 
mostly W 
women 
616 incident 
AF 
Median 
14.5yrs 
 
Never 
Ever smoker NA 
Multivariable-adjusted 
Reference 
1.29 (1.06-1.57) p=0.01 
Rodriguez et al.112 
Multi-Ethnic Study 
of Atherosclerosis 
 
Cohort 
Incident AF 
6,721 
Multi-ethnic 
305 incident 
AF 
Mean 
6.98 yrs 
All races 
Never 
Former 
Current 
 
 
Chinese 
Hispanics 
Non-Hispanic B 
Non-Hispanic W 
AF† 
42.9% 
46.2% 
10.9% 
 
 
NA 
No AF† 
50.7% 
36.1% 
13.2% 
 
 
NA 
 
 
 
 
Age- & sex-adjusted population  
attributable fraction current smoking  
-0.7 (-17.7 to 46.9) 
-0.9 (-21.1 to 15.8) 
27.0 (5.8 to 43.5) 
6.9 (-1.3 to 14.4) 
Heeringa et al.114 
Rotterdam Study 
Cohort 
Incident AF 
5,668  
W 
371 incident 
AF 
Median 
7.2 yrs 
Never smoker 
Current 
Former 
 
  78/1280 
160/2159 
Multivariable adjusted 
1.51 ( 1.07-2.12) 
1.48 (1.12-1.96) 
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Table 7. Smoking and risk of AF 
Study Design Subjects FU Tobacco  AF, % Multivariable Risk (95%CI) 
Huxley et al.18 
Atherosclerosis Risk 
in Communities 
Cohort 
Incident AF 
14,598 
B&W 
1520 
incident AF 
Mean  
17.1 yrs 
 
 
 
Never 
Former 
 
Current 
Incidence 
rate/1000py 
 
4.23 
5.76 
 
7.45 
Population 
Attributable 
Fraction 
0 
2.06 (-2.05-
6.05) 
9.78 (6.74-
12.9) 
Relative hazard – adjusted  
Note reference is current smokers 
 
0.55 (0.48-0.62) 
0.60 (0.52-0.68) 
 
Reference 
Schnabel et al.115 
Framingham Heart 
Study 
Cohort 
Incident AF 
4,764 
W 
457 incident 
AF 
Max  
10yrs 
Current NA Age- and sex-adjusted 
1.08 ( 0.88–1.33) p=0.47 
Not included in multivariable risk 
prediction instrument 
Psaty et al.116 
Cardiovascular 
Health Study 
Cohort 
Incident AF 
4,844 
B & W 
304 incident 
AF 
Mean  
3.28 yrs 
Current smoking NA Did not enter multivariable model 
Frost  et al.117 
Danish Diet, 
Cancer, and Health 
Study 
Cohort 
Incident AF 
47,589  
W 
553 incident 
AF 
Mean  
5.7 yrs 
Never - reference 
Former 
Current 
NA Men 
0.80 (0.62–1.04)  
0.83 (0.64–1.07) 
Women 
0.94 (0.65–1.36) 
0.95 (0.66–1.35) 
Wilhelmsen et al.118 
Multifactor Primary 
Prevention Study, 
Göteborg 
Cohort 
Incident 
hospitalized AF 
7,495  
W Men 
754 incident 
AF 
Mean  
25.2 yrs 
Never + ex-
smoker 
1-14 cig/day 
>15 cig/day 
10.6 
  9.1 
11.8 
Reference* age-adjusted 
0.83 ( 0.71-0.97) 
1.16 ( 0.73-1.86) 
Nyrnes et al.30 
Tromsø study 
Cohort 
Incident AF 
22,815W 
822 incident 
AF 
Mean  
11.1 yrs 
Current smoking 
No AF 
AF 
Men 
37.1% 
24.3% 
Women 
36.7% 
22.7% 
Not included in multivariable model 
Stewart et al.119 
Renfrew/Paisley 
study 
Cohort 
Prevalent AF 
Incident AF 
 
15,406 
W 
100 
prevalent AF 
537 incident 
of 8,532 in 
f/u 
20 yrs Current or former 
Prevalent AF 
No AF 
(n=15,306) 
AF (n=100) 
Men* 
81.2% 
79.0% 
Women* 
54.1% 
65.8% 
*Age-adjusted prevalence 
Not significantly associated in age-
adjusted analyses; not selected for 
inclusion in multivariable analyses for 
prevalent or incident AF 
Hergens et al.126 
Swedish cohort 
studies 
7 Cohort 
studies 
Incident AF 
127,907 W  
men never 
smoker 
3,494 
incident AF 
 Prevalence of 
Snus use 25% 
 
 Adjusted for age and BMI 
 
1.07 (0.97-1.19) 
(b) Hospital-based       
Suzuki et al.113 
Shinken database 
New patients 
attending 
Cardiovascular 
Institute 
Incident AF 
15,221 
Japanese 
190 incident 
AF 
Mean  
2 yrs 
Max  
8.1yrs 
Nonsmokers 
Smokers 
Former 
Current  
Brinkman 
index≥800 
5.0/1000 py  
9.0/1000 py 
8.6/1000 py 
9.8  /1000py 
10.6/1000py 
Reference, adjusted analyses 
1.47 (1.09–2.00) 
1.33 (0.94–1.89) 
1.81(1.17–2.79) 
1.69 (1.05–2.70) 
(c)Internet-based survey 
Dixit et al.122 
Health eHeart Study 
Self-referred 
internet 
self-report 
Prevalent AF 
 
4,976 
~80% W 
593 
prevalent AF 
Cross-
sectional 
 
 
Never 
Past 
Current 
 
AF 
52.7% 
43.6% 
3.8% 
 
No AF 
66.5% 
29.5% 
4.0% 
 
Unadjusted p-value,  
 
 
p<0.001 
 
Median yrs 
smoked, past & 
current smokers 
 
18 
 
12 
Unadjusted p-value 
p<0.001 
Secondhand 
smoke 
Smoking parent 
during gestation 
Residing with 
smoker 
AF 
68% 
 
39% 
No AF 
51% 
 
26% 
Multivariable adjustment 
OR 1.37 (1.08-1.73) p=0.009 
 
OR 1.40(1.10–1.79)  p=0.007 
*AF incidence not depicted by smoking status; †Personal communication Carlos J. Rodriguez, MD, MPH 10/26/2015 
AF – atrial fibrillation, B – Black, BMI – body mass index, CI – confidence interval, cig. – cigarette, CVD – cardiovascular disease, DM – diabetes 
mellitus, FU – follow-up, HR – hazard ratio, HT – hypertension, NA – not available, OR- odds ratio, pts- patients, py - person years, W – White, yrs- 
years 
 356 
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Air pollution  357 
Experimental and epidemiological studies have indicated that air pollution is related to an increased 358 
prevalence of cardiovascular risk factors, for example diabetes mellitus and hypertension, as well as 359 
cardiovascular disease (148-153). Fine particular matter (PM2.5) produced by burning fossil fuels may 360 
contribute to this relationship. The underlying pathophysiology has been attributed to an increased 361 
inflammatory response to high particle exposure, influencing the autonomous nervous system (152).  362 
Although fine particle pollution has been linked to stroke in several studies (154-156), it has not been 363 
found to be associated with the induction of AF. Likewise, epidemiological studies have failed to show a 364 
relationship between permanently higher fine particle exposure and AF incidence (157, 158) (Table 8). 365 
Short-term exposure may directly enhance AF susceptibility in patients with cardiac disease (159, 160).  366 
Table 8. Relation of air pollution to risk of AF 
Study Design Subjects FU Particle 
pollution 
AF Risk 
Link et al.
159
 
Tufts Medical 
Center Cardiac 
Arrhythmia 
Center 
Prospective 
cohort 
study; acute 
exposure 24 
hrs prior 
176; ICD pts 1.9 
yrs 
PM2.5,  sulfate, 
NO2, SO2, O3 
328 
episodes of 
AF >30s 
Odds of AF 
increased by 26% for each 6.0 
μg/m3 increase in PM2.5 in the 2 
hrs prior to the event (p=0.004) 
Milojevic et al.
157
 
Myocardial 
Ischaemia 
National Audit 
Project (MINAP)  
Case-cross-
over design 
2,867,473  
CV events; 
mean age 73 yrs 
6 
yrs 
CO, NO2, PM10, 
PM2.5, SO2, O3; 
Lags up to 4 
days 
310,568 pts 
with AF 
NO2 increased risk for AF 2.8% 
(0.3 to 5.4) 
Bunch et al.
158
 
Utah‟s Wasatch 
Front  
Case-
crossover 
study design 
10,457 AF 
hospitalizations 
15 
yrs 
PM2.5; day 
Exposure and 
cumulative 
lagged 
exposures for 
up to 21 days 
100% No association between PM2.5 and 
hospitalization for AF 
AF – atrial fibrillation, CV- cardiovascular, FU-follow-up, ICD – implantable cardioverter-defibrillator,  PM2.5 –particular fine 
particular matter, pts – patients, hrs-hours, yrs – years, s- seconds 
 367 
 368 
 369 
 370 
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Caffeine  371 
Caffeine is a methylxanthine compound that is chemically similar to theophylline. Caffeine  is 372 
present in tea, coffee, cola or energy drinks. It has several cardiovascular effects increasing neurohormonal 373 
and sympathetic nervous system stimulation (161). Therefore, caffeine has been addressed as a potential 374 
trigger for AF.  375 
The acute effects of high caffeine loading or even intoxication show minor and overall inconsistent 376 
evidence for increased susceptibility to supraventricular arrhythmias (162-164). Habitual caffeine ingestion 377 
has been investigated in several prospective cohort studies (Table 9), but these failed to show any significant 378 
relationship to incident AF (165). Also, heavy coffee drinking (166) failed to demonstrate a significant 379 
relationship between caffeine and AF or flutter even in very high consumers (10 cups, 1000 mg/day). 380 
Overall, caffeine consumption on a habitual and regular basis does not seem to increase the incidence of AF 381 
(35, 166, 167). However, other forms of caffeine ingestion such as energy drinks containing other stimulants 382 
such as taurine in combination with alcohol, may possibly contribute to an increase of risk, at least in case 383 
reports (168). 384 
 385 
Table 9. Caffeine use and risk of AF 
Study  Design Subjects FU Caffeine 
Assessment 
AF Caffeine consumption in mg/dl 
and corresponding hazard 
ratio 
Conen et al.
167
 
Women´s Health 
Study 
Cohort,  
USA 
33,638 
100% 
female mean 
age 53 yrs 
14.4 yrs 
 
Food Frequency 
Questionnaire 
n=945 Quintiles: 
22         1.0 
135       0.88 
285       0.78 
402       0.96 
656       0.89 
Shen et al.
35
 
Framingham 
Heart Study 
Cohort,  
USA 
4,526 
56% female 
mean age 62 
yrs 
4 yrs 
 
Food Frequency 
Questionnaire 
n=296 Quartiles: 
23         1.0 
142       0.84 
347       0.87 
452       0.98 
Frost et al.
166
 
Danish Diet, 
Cancer, and 
Heart Study 
Cohort, 
Denmark 
47,949 
54% female 
mean age 56 
yrs 
5.7 yrs 
 
Food Frequency 
Questionnaire 
n=555 Quintiles: 
248      1.0 
475      1.12 
584      0.85 
769      0.92 
997      0.91 
AF – atrial fibrillation, FU – follow-up, yrs - years 
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  386 
Alcohol consumption  387 
Alcohol as a cause of AF has been recognized in the setting of acute consumption, commonly 388 
described as the “holiday heart” (169). Binge drinking (>5 drinks on a single occasion) is associated with an 389 
increased risk of new onset AF (170).  390 
A variety of mechanisms has been proposed for the role of alcohol in contributing to AF as triggers 391 
or substrate for the arrhythmia including decreased vagal tone, hyper-adrenergic state, direct toxic effect on 392 
the cardiomyocytes, altered atrial conduction and shortening of refractoriness (171-173). 393 
In evaluating the contribution of chronic alcohol consumption to the development of AF, an 394 
important limitation is that unlike the objective measures available for many of the established risk factors 395 
for AF, the quantification of alcohol consumption is based on self-reported levels. Most studies have found 396 
an association between heavy alcohol consumption and incident AF (Table 10).  For example, the 397 
Copenhagen City Heart Study observed that men consuming >35 drinks/week had a high risk of AF (174). 398 
Similarly, the Framingham cohort study suggested that heavy alcohol consumption (>36 g/day) significantly 399 
increased the risk of AF (175). The Women‟s Health Study showed that consumption of >2 drinks/day was 400 
associated with an increased risk of AF (176). A consistent increase in risk of AF with chronic, heavy 401 
alcohol consumption was confirmed in a meta-analysis, which also demonstrated that the association 402 
between AF and alcohol consumption was linear (177).  403 
Although these large epidemiological datasets have confirmed the association of heavy alcohol 404 
consumption with AF, recent studies have implicated a contributory role of even small quantities of alcohol 405 
with an increased risk of AF. Data from 2 large prospective Swedish cohorts comprising 79,000 individuals 406 
show that, when compared to <1 drink per week, the consumption of 15-21 and >21 drinks per week 407 
conferred significant risks of developing AF on multivariable analysis (178). This study identified that the 408 
risk for AF may be most pronounced with liquor; modest for wine and no excess risk was detected with 409 
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beer. In addition, one meta-analysis of 7 prospective studies suggested that there was a greater risk of AF 410 
with even low levels of alcohol consumption (178). In both men and women, each drink of alcohol was 411 
associated with an 8% increase in relative risk of AF. 412 
The consistent epidemiologic relationship between alcohol and AF has led to the suggestion that 413 
lowering alcohol consumption may be an effective AF preventive strategy (179). Recent studies have also 414 
highlighted the importance of aggressive risk factor management, including reducing alcohol consumption, 415 
in maintaining sinus rhythm in patients with established AF. In obese and overweight individuals, these 416 
studies have established an ultimate goal of reducing alcohol consumption to ≤30 g/week (147). In the 417 
context of a directed management of risk factors, reducing alcohol consumption has contributed to short 418 
term improvements in AF burden (26) and AF ablation outcomes (147), as well as long-term maintenance of 419 
sinus rhythm (28). The above evidence perhaps confirms some atrial toxicity related to alcohol consumption. 420 
Thus, physicians must not neglect obtaining a detailed history on alcohol consumption and providing 421 
appropriate counselling to reduce alcohol intake, when necessary, in patients with AF.  422 
 423 
Table 10. Risk of AF and alcohol consumption 
Study Design Subjects FU  Alcohol,  
drinks/day  (week) 
AF, n Risk (95%CI) 
(a) Population cohorts 
Mukamal et al. 174 
Copenhagen City 
Heart study 
Prospective 
cohort 
16,415 
Men and 
Women 
Free of AF at 
baseline 
26 yrs 
 
 
Men 
Multivariable risk 
<1 drinks/week 
≥35 drinks/week: 
 
Adjusted for CHD, 
CHF, BP 
 
 
Women 
Multivariable risk 
<1 drinks/week 
21-27 drinks/week 
1071  
 
Reference (risk in HR) 
1.45 (1.02-2.04)  
 
HR 1.63 (1.15-2.31)  
In men 5% of incident AF is 
attributable for heavy 
drinking 
 
 
Reference (risk in HR) 
1.04 (0.64–1.70) p=0.87 for 
trend 
Conen et al. 176 
Women Health 
Study 
Prospective 
cohort 
34,715 
Women <45 yrs 
Free of AF  
12.4 yrs 
median 
 
0 drinks/day 
≥2 drinks/day 
653  
Reference (risk in HR) 
1.6 (1.13-2.25) 
Djousse et al. 175 
Framingham Heart 
Study 
Prospective 
cohort 
Case- control 
analysis 
1,055 who 
developed AF   
4672 controls 
Men and women 
>50 yrs  
0 gr/day 
>36 gr/day 
1055  
Reference (risk in OR) 
1.34 (1.01-1.78) 
Larsson et al. 178 
Swedish Cohort 
Study 
Prospective 
cohort 
79,019 
Men and women 
free of AF at 
baseline 
12 yrs Dose response* 
<1 drink/week  
15-21 drinks/week 
>21 drinks/week 
7245  
Reference (risk - RR) 
1.14 (1.01-1.28) 
1.39 (1.22-1.58)  
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Binge drinking (>5 
drinks/single occasion) 
 
Type of drinks 
Liquor 
7-14 drinks/week 
>14 drinks/week 
Wine 
>14 drinks/week 
Beer 
 
 
1.13 (1.05-1.32) 
 
 
 
1.13 (1.01–1.28) 
1.43 (1.14–1.74) 
 
1.30 (1.06–1.61) 
NS 
Kodama et al.177 Meta-analysis 
14 observational 
cohort and case-
control studies 
14 studies 130,820 
participants 
7558 cases 
 
9 studies  126051 
participants 
6341 cases 
2.5-44 yrs Overall  
Highest vs lowest 
alcohol intake 
 
Dose-response  
(4-86.4 gr/day) 
 
7558 
 
 
6341 
 
Pooled OR/RR 
1.51 (1.31-1-74) 
 
 
RR 1.8 (1.05-1.10) per 10gr 
alcohol per day 
Larsson et al.178 Meta-analysis 7 
prospective 
cohort studies 
206,073 participants  
12,554 cases 
Men, women 
 
4.7 to >50 
yrs 
0 drinks/day* 
1 drink/day 
2 drinks/day 
3 drinks/day 
4 drinks/day 
5 drinks/day 
Overall  
12554 Reference (risk in RR) 
1.08 (1.06- 1.10) 
1.17 (1.13- 1.21)  
1.26 (1.19- 1.33)  
1.36 (1.27-1.46)  
1.47 (1.34-1.61)  
1.08 (1.06-1.10)  
8% (6-10%) increase  
in AF risk per 1 drink/day 
increment 
(b)Intervention studies 
Pathak et al.147 
ARREST-AF 
Prospective 
cohort study 
281 pts with AF 
undergoing catheter 
ablation  
68 pts RFM 
88 pts controls 
2 yrs RFM - Alcohol <30g/ 
week+ BP, lipids and 
glycemic control, 
weight reduction, 
smoking cessation 
vs control 
- RFM predictor of arrhythmia 
free survival 
HR 4.8 (2.04-11.4)  
AF- atrial fibrillation, BP- blood pressure, CHD – coronary heart disease, CHF – chronic heart failure,  CI-confidence interval, FU- follow-up, HR- 
hazard ratio, OR – odds ratio, RR- relative risk, RFM – risk factor modification, pts – patients, yrs- years  
*Standard drinks = 12 g alcohol. One standard drink corresponds to approximately 40 ml liquor, 80 ml strong wine, 150 ml wine, 330 ml class III 
beer (alcohol by volume, >3.5%), 50 ml class II beer (2.8% to 3.5%), or 660 ml class I beer (<2.25%). 
 424 
Recreational drugs 425 
There are numerous reports on the effects on myocardial infarction, ventricular arrhythmias and 426 
sudden cardiac death caused by recreational (illicit) drugs such as amphetamine, cocaine and cannabis (180). 427 
However, data on these drugs as risk factors for AF per se are sparse. AF has not been reported to be 428 
associated with amphetamine, heroin or LSD abuse and there are limited reports on the  abuse of cannabis, 429 
cocaine, ecstasy and anabolic-androgenic steroids with AF.  430 
Cannabis is the most commonly used recreational drug, which is increasing in Europe. A systematic 431 
review and a case series with literature review reported that all cases of cannabis-related AF were among 432 
young people without co-morbidities (181, 182). The underlying mechanism is probably adrenergic 433 
stimulation and disturbance in microvascular flow facilitating AF development by increased pulmonary vein 434 
ectopy. Cannabis abuse leading to AF is not benign in young and healthy subjects as it may contribute to 435 
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atrial remodeling long-term (183). AF caused by cannabis abuse may be more malignant in older patients 436 
having other risk factors for thromboembolism. The burden of this problem is probably underestimated, 437 
given that most illicit cannabis users avoid seeking medical care unless serious disease is present.   438 
Physicians should carefully examine for recreational drug abuse in young new onset AF patients 439 
without known predisposing factors.  One case report describes AF in a healthy adolescent who had used 440 
ecstasy (184).  Anabolic androgenic steroids are often used by young athletes to increase their capacity. 441 
Thus AF in a young healthy athlete should raise the suspicion that illicit drugs may be a possible cause and 442 
lead to careful search for drug abuse in order to prevent AF and more serious cardiac consequences (185, 443 
186).  444 
 445 
Medications 446 
A number of cardiovascular and non-cardiovascular drugs have been associated with increased risk 447 
of AF (Table 11). Drug-induced AF has received relatively little attention, and the exact incidence is not 448 
known.  449 
Many cardiovascular (adenosine, dobutamine, ivabradine) and non-cardiovascular [nonsteroidal anti-450 
inflammatory drugs (NSAIDS), high-dose corticosteroids, and respiratory medications as aminophylline] 451 
drugs can induce AF (187-189).  Adenosine is reported to induce AF when used for terminating 452 
supraventricular tachycardia with atrioventricular nodal involvement. Many patients undergoing cardiac 453 
surgery and treated with the inotrope dobutamine may develop postoperative AF. However, AF is usually 454 
transient and of short duration. Evidence of chemotherapy-induced AF has been summarized (187, 190). 455 
Anthracyclines, melphalan, interleukin-2 and cisplatin appear to be associated with AF, in addition to cancer 456 
itself that creates an inflammatory arrhythmogenic milieu (191).   Several case reports of antipsychotic drugs 457 
associated with AF have been published (192), include with olanzapine (used for treatment of schizophrenia 458 
and bipolar disorder) . The antiemetic drug ondansetron is probably related to AF (187).  459 
Whether bisphosphonate drugs against osteoporosis are associated with AF remains somewhat 460 
controversial. A systematic review and meta-analysis from 2014 concluded that AF risk is increased by 40% 461 
with intravenous use and 22% by oral use (193). A more recent meta-analysis stated that bisphosphonates 462 
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may modestly increase the risk of AF, but given the large reduction in fractures with these drugs, the authors 463 
did not recommend changes in treatment (194).  464 
Drug-induced AF can occur through pharmacological stimulation promoting ectopic impulses or by 465 
modulating the underlying substrate. Further research is perhaps needed to determine the incidence and risk 466 
factors of drug-induced AF, and particularly whether specific medications increase the risk of 467 
thromboembolism or mortality. In patients with a new-onset AF, it is reasonable to review the 468 
pharmacological history to identify whether any of the prescribed drugs may be responsible for the 469 
arrhythmia and make a balanced judgment on the risks and benefits of the drug use. Drug-induced AF may 470 
appear in healthy patients, but occurs more frequently in the elderly, after cardiac surgery, and if 471 
comorbidities and risk factors associated with AF are present. These risk factors include polypharmacy, 472 
hypertension, major heart disease, chronic obstructive pulmonary disease and sleep apnea. 473 
 474 
Table 11. Medications associated with risk of incident AF 
 Medications 
Common (> 20 %) Dobutamine
187
, Cisplatin
187, 190
 
Infrequent (5-20 %) Anthracyclines
187, 190
, Melphalan
187, 190
, Interleukin-2
187, 190
, NSAIDS
189
, Bisphosphonates
193, 194
 
Rare (<5 %) Adenosine
187
, Corticosteroids
187
, Aminophylline
187
, Antipsychotics
192
, Ivabradine
188
 
Ondansetron
187
 
 475 
 476 
Psychological distress   477 
Psychological distress is prevalent among AF patients (195, 196, 197, 198, 199); approximately 25-478 
50% have symptoms of anxiety and/or depression and fear and worry are common (195-202). There is some 479 
evidence from ICD patients that acute emotional distress (particularly anger and anxiety) (197, 203, 204) 480 
and depression (205) may be antecedents to ventricular arrhythmias but there are no data in ICD patients 481 
regarding atrial arrhythmias. Only three studies have specifically examined the impact of psychological 482 
distress on incident AF (206-208). 483 
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The Framingham Offspring Study examined the association between Type A behaviour, anger, and 484 
hostility and incident AF. In age-adjusted analyses, anger-out predicted incident AF in women, while trait 485 
anger, symptoms of anger, and hostility predicted onset of AF in men (206) (Table 12).  On multivariable 486 
analyses, symptoms of anger, hostility, and trait-anger predicted the 10-year incidence of AF in men but not 487 
in women (206). Another analysis of this cohort investigated the effect of tension and anxiety on the 488 
development of AF (207). In age-adjusted analyses, tension and anxiety predicted development of AF in 489 
men only.  After adjustment for confounders, only tension was an independent predictor of incident AF but 490 
only among men (207).  491 
The absence of an association between psychological distress and development of AF in women was 492 
confirmed in the Women‟s Health Study (208).  In this cohort of 30,746 female health professionals aged 493 
≥45 years who were free from cardiovascular disease at baseline, 771 (2.51%) developed AF over a median 494 
10-year follow-up period.  Psychological distress was not associated with incident AF in age-adjusted or 495 
multivariable analyses (208).  These findings require replication in other more diverse populations since 496 
these cohorts were predominantly white, middle-class, and middle-aged (204-208) and the effect sizes in the 497 
Framingham Offspring study were modest (207, 208). 498 
Psychological distress, particularly depression, is more commonly associated with adverse lifestyle 499 
choices (smoking, excessive alcohol intake, poor diet, physical inactivity), poorer adherence to medication 500 
etc., all of which may increase the likelihood of development of other risk factors for AF, and hence 501 
predispose people to incident AF. It is also plausible that the autonomic nervous system may be the conduit 502 
by which AF is linked with psychological distress and vice versa.  The current evidence is therefore limited 503 
and equivocal, and future research is needed. 504 
  505 
Table 12. Psychological distress and risk of AF 
Study Design Subjects 
N (% 
women) 
FU, 
yrs 
Psychologic
al distress 
measures 
AF, n 
(%) 
Age-adjusted risk 
RR (95% CI) 
Multivariable-adjusted 
risk RR (95% CI) 
Eaker et al206 
Framingham 
Offspring 
Prospective, 
observational 
cohort 
3,682 
(52%) 
 
10 Type A 
behaviour 
Anger 
Women: 
62/1908 
(3.2%) 
Women: 
Anger-out  
1.3(1.0-1.6); p<0.05 
Womena: NS 
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Study Mean age 
48.5 (10.1) 
yrs 
Hostility  
Men: 
132/1750 
(7.5%)† 
 
Men: 
Trait anger  
1.2 (1.0-1.4); p<0.05 
Symptoms of anger 
 1.2 (1.1-1.4); p<0.05 
Hostility 1.3 
(1.1-1.6); p<0.05 
 
Mena: 
Trait anger  
1.1 (1.0-1.4); p=0.04 
Symptoms of anger  
1.2 (1.1-1.4); p=0.008 
Hostility  
1.3(1.1-1.5); p=0.03 
Eaker et al207 
Framingham 
Offspring 
Study 
Prospective, 
observational 
cohort 
3,682 
(52%) 
 
Mean age 
48.5 (10.1) 
yrs 
10 Tension 
Anxiety 
Women: 
62/1908 
(3.2%) 
 
Men: 
132/1750 
(7.5%) 
† 
Women: ‡ 
 
 
 
Men: 
Tension 1.28 
(1.08-1.52) 
Anxiety 1.16 
(1.01-1.33) 
Womena: 
Tension 0.83 (0.63–1.11) 
Anxiety 1.03 (0.81–1.31) 
 
Mena: 
Tension 1.24 (1.04-1.48) 
Anxiety 1.10 (0.95–1.27) 
 
Whang et al208 
Women‟s 
Health Study 
RCT, plus 
observational 
follow-up 
30,746 
women 
without 
CVD at 
baseline 
 
Age:  
≥45 years 
10.5 MHI-5* 
 
MHI-5 score: 
86-100  
76-85 
53-75 
<53 
 
 
 
359 
235 
129 
48 
 
 
 
Reference 
0.86 (0.73-1.02) 
0.91 (0.74-1.11) 
1.08 (0.80-1.47) 
p-value for trend 0.61 
 
 
 
Reference 
0.87 (0.73-1.03) 
0.89 (0.72-1.09) 
0.99 (0.72-1.35) 
p-value for trend 0.34 
a Adjusted for age, diabetes, hypertension, history of myocardial infarction or history of congestive heart failure, and valvular heart disease (defined as any diastolic 
murmur or ≥3 out of  6 systolic murmur). 
† not reported by each psychological measure; ‡ not reported for women; * score <53 indicates significant global distress 
AF- atrial fibrillation, CI-  confidence interval, CVD- cardiovascular disease, FU- follow-up, MHI-5 - Mental Health Inventory 5-items, NS- not significant in 
multivariable analyses, RCT- randomised controlled trial, RR- relative risk, SD- standard deviation, yrs-years 
 506 
Physical activity and inactivity 507 
Physical activity has profound benefits on lowering cardiovascular morbidity and mortality and 508 
physical inactivity is a major risk factor for cardiovascular disease. The effects of physical activity on the 509 
development of AF are less well documented and intervention studies on physical activity and the 510 
development of AF are lacking (Table 13).  511 
The risk of AF depends on the interaction between individual susceptibility, environment and the 512 
degree of physical activity (209).  Vigorous exercise may increase risk of sudden cardiac death, and even AF 513 
in some instances; however, habitual moderate physical activity may have several benefits that can reduce 514 
the incidence of AF. Lowering heart rate, blood pressure, better glucose and lipid control, weight loss, 515 
improved endothelial function, and lower systemic inflammation are some of the benefits of exercise that 516 
may decrease the development of AF (97). On the other hand, vigorous activity can cause acute 517 
cathecholamine fluxes, autonomic tone changes, and atrial stretch, all contributing to AF risk (210-215). 518 
Autonomic influences should also be taken into consideration to decrease aggravation of AF (210, 216).  519 
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The Euro Heart Survey on AF showed that an autonomic trigger pattern, either adrenergic, vagal or 520 
mixed was present in 33% of patients; however, physicians did not choose rhythm or rate control 521 
medications according to those triggers (216), and inappropriate therapy in vagal AF patients enhanced 522 
progression of AF.   523 
As stated earlier, obesity begets AF, and increased cardiorespiratory fitness is protective against 524 
incident AF. Indeed, the CARDIO-FIT study showed that arrhythmia free time was greatest in obese 525 
patients with high cardiorespiratory fitness. In this study, AF burden and symptom severity significantly 526 
decreased in the group with cardiorespiratory fitness gain over 2 metabolic equivalent tasks (METs) (27) 527 
Different studies have suggested a possible relationship between endurance training and the 528 
development of AF, although this has not been confirmed in all studies or a Cochrane meta-analysis (217-529 
224). Most studies have looked at the effects of endurance training and vigorous exertion in young and 530 
middle aged adults. In a study of 44,410 men, intense endurance training at age 30 increased risk of AF later 531 
in life whereas moderate intensity decreased AF risk (225). Similar findings were reported in older athletes 532 
(226). A meta-analysis of several small studies showed that risk of AF development in athletes was more 533 
than in nonathletes, but referents were not age matched and there was variance in the level of endurance 534 
across studies (227). Age, years of training and type of sport will all affect the outcome, therefore it is not 535 
possible to deduct a net conclusion from these studies except that vigorous endurance exercise may have a 536 
possible and small facilitating effect on AF. 537 
In older adults, prospective epidemiological studies have shown a U-shaped relationship between 538 
level of physical activity and risk of AF. For example, the Cardiovascular Health Study demonstrated that 539 
leisure time activity was associated with lower AF incidence in a graded manner with lower risk as the 540 
intensity increased (226). AF incidence was lower in those with moderate exercise compared to no exercise 541 
(HR 0.72, 95% CI 0.58 to 0.89). However high-intensity exercise was not associated with a significantly 542 
reduced risk of AF (HR 0.87, 95% CI 0.64 to 1.19). There is also a graded inverse relationship between 543 
cardiorespiratory fitness and incident AF especially in obese patients (228). In a large population based 544 
Swedish cohort, the risk of AF decreased with increased leisure time exercise in middle aged and elderly 545 
women (229). Inactivity and obesity may lead to diastolic dysfunction and left atrial enlargement, and 546 
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therefore increased AF risk whereas exercise training improves diastolic function and reduces left atrial 547 
volume (230). 548 
Current evidence would suggest that moderate physical activity is associated with better 549 
cardiovascular health, decreased mortality and decreased risk of AF. The on-going Routine versus 550 
Aggressive upstream rhythm Control for prevention of Early atrial fibrillation in moderate heart failure 551 
(RACE 3) trial is investigating whether the combination of renin–angiotensin–aldosterone system (RAAS) 552 
modulators, statins, and cardiac rehabilitation interventions to promote a better lifestyle including physical 553 
activity, weight reduction and a healthy diet, may reduce progression of AF (231).  554 
 555 
Table 13. Physical activity and risk of AF 
Study Design Subjects Age, 
years 
FU, 
years 
Physical activity AF,% Risk 
Population cohorts 
Qureshi et al. 228 
(FIT project) 
patients referred for 
treadmill  
Retrospective  69,885 
 
54.5 5.4  Graded by 
treadmill 
7  1 Met higher decreases AF risk 
by 7 % 
Drca et al.229 
Swedish 
Mammography 
Cohort 
Healthy 
Prospective 36,513 
women 
60  10 Level of leisure 
activity 
7.9  AF risk decreases with 
increased level of activity 
Mozaffarian et al. 226 
Cardiovascular 
Health Study 
Prospective 5,446  
Men and 
women 
Over 65 
 
10  Exercise intensity 19  AF less with low to moderate 
exercise 
Grimsmo et al. 220 
Cross country skiers 
Prospective 122 and 
117 
  
Over 54 28-30  High in all 12.8 Endurance training increases 
AF 
Myrstad  et al. 232  
Male, cross country 
skiers 
Retrospective 3,712  
 
Over 53 
 
 High in all 12.5 Endurance training increases 
AF 
Lee et al. 219 
Leisure-time running 
Longitudinal 
cohort study 
309,540 
Men and 
women 
40-45 
 
4  Leisure time 
activity 
0.4  AF increases with self-reported 
activity in men 
Thelle et al. 233 
Walkers and runners 
Proportional 
hazards 
analysis of  
14,734 
  
All 
ages 
6.2 Walking or 
running 
1.9-2.7  
(arrhythmia)  
AF similar in walkers and 
runners 
Arrhythmia decreases per MET  
Aizer et al.234 
Physicians Health 
Study Healthy men 
Prospective 16,921 
 
40-84 12  Degree of physical 
activity 
9.8 Vigorous activity increases AF 
AF – atrial fibrillation, FU – follow-up, MET – metabolic equivalent task, pts- patients  
 556 
 557 
Genetic predisposition and risk of AF 558 
 559 
About 5% of patients with AF and 15% with lone AF referred for evaluation of arrhythmias have family 560 
history of arrhythmias (235). Population-based studies demonstrated  association between family history and 561 
risk of AF development (236-241) (Table 14), which become stronger with increased numbers of affected 1
st
 562 
degree relatives and younger age.  Several genes and loci  linked to  AF and its substrate were identified in 563 
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families, individuals, and different populations (242-244),   still there are genes in development state with 564 
unknown effects and risk associated with AF (245, 246). AF with genetic predisposition is defined as 565 
monogenic when  related to inherited cardiomyopathies and as  polygenic in  presence of common gene 566 
variants associated with early AF onset in population (247, 248).   567 
The evidence of genetic predisposition to AF is evolving, and more studies are needed to clarify the role of 568 
various genes in AF development and  as the genetic predisposition is a non-modifiable risk factor more 569 
studies are needed to establish whether intervention on modifiable risk factors can decrease risk of AF in 570 
populations with genetic  predisposition.   571 
 572 
Table 14. Genetic predisposition and risk of AF – population-based studies 
Study Design Subjects FU Familial AF 
history  
AF,% Risk* (95%CI) 
Fox et al
236
 
Framngham 
Heart Study 
Prospecti
ve cohort  
Populatio
n-based 
epidemio
logical 
study 
2243 O 
1165 women 
1078 men 
At least 30 yrs 
16  
yrs 
681 – at least 1 
parent had 
documented AF 
 
N=70 Parental AF vs No FH 
OR 1.85 (1.12-3.06; p =0.02) 
Parental AF vs No FH <75 yrs 
(O and P) 
OR 3.23 (1.87-5.58; p<0.001) 
Parental AF vs No FH <75 yrs 
(O w/o overt clinical heart 
disease) 
OR 3.17 (1.71-5.86; p<0.001) 
Arnar et al.
237
 
Iceland cohort 
Populatio
n-based 
cohort 
 
5269 pts with 
AF 
- AF risk in 1
st
- 5
th
 
degree relatives  
- 1
st
 degree relative 
RR 1.77 (1.67=1.88 p=0.001) 
1
st
 degree relative <60 yrs old 
RR 4.67 (3.57-6.08, p=0.001) 
Gundlund et 
al.
238
 
Denmark cohort 
Populatio
n-based 
study 
New-onset AF  
67,310 
mothers- 64yrs  
103,822 
fathers -70yrs 
11,800 
siblings-46yrs  
 AF screening: 
 
133,516 maternal O 
221,774 paternal O 
21, 448 sibling O 
 
 
2536(1.9%)  
2906(1.3%)  
292 (1.4%) 
RR compared to general 
Denmark population  
3.37 (3.21–3.53) 
 2.81 (2.69–2.93)  
5.20 (4.61–5.85)  
Zoller et al.
239
 
Sweden cohort 
Populatio
n-based 
case-
controlle
d study 
300,586 
individuals 
with AF/AFl 
multiplex 
families 
  
1 parent 
≤49yrs 
2 parents 
≤49yrs 
≥1 sibling 
≤49 yrs 
≥2 siblings 
≤49 yrs 
Case vs Control 
22.6% vs 13.6% 
22.8% vs11.9% 
2.0% vs 0.2% 
2.1% vs 0.5% 
14.7% vs 5.6% 
8.1% vs 2.3% 
2.9% vs 0.6% 
1.4% vs 0.2% 
 
OR 1.95(1.89-2.00) 
OR 2.33 (2.23-2.44) 
OR 3.6 (3.3-3.92) 
OR 5.04 (4.36-5.28) 
OR 3.08 (3.0-3.16) 
OR 4.06 (3.79-4.41) 
OR 5.72(5.28-6.19) 
OR 8.51(6.49-11.15) 
Lubitz et al.
240
 
Framingham 
Heart Study  
Prospecti
ve cohort 
4421 
participants  
-  
Familial AF - 1185 
Premature familial 
AF (<65 yrs) -351 
 
Overall 440  
Familial AF vs 
no FH 
 5.8% vs 3.1% 
 
Presence of any 1
st
 degree 
familial AF  vs no 
HR 1.4 (1.13-1.74, p=0.002) 
Presence of premature familial 
AF (<65yrs) 
HR 2.01 (1.49-2.71, p<0.001) 
Number of 1
st
 degree relative 
with AF- risk per each 
additional affected member 
HR  1.24 (1.05-1.46, p=0.01) 
Oyen et al.
241
 Prospecti 3,985,446 31yr 1st degree relative n =269 IRR 3.48 (3.08–3.93) 
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Denmark cohort ve cohort individuals 
Lone AF - 
9,507 subjects 
<60 yrs 
 
 
s 2
nd
  degree relative 
 
Number of affected 
1
st
 degree relatives 
1 affected  
≥2 affected 
 
Age at onset of lone 
AF for cohort 
member and 1
st
 
degree relative  
 <30 yrs for both  
<40yrs for both 
n=19 
  
 
 
n=264 
n=5 
 
 
 
 
 
N/A 
n=31 
IRR 1.64 (1.04–2.59) 
 
 
 
IRR 3.45 (3.05-3.9) 
IRR 6.24 (2.59-15.0) 
 
 
 
 
 
IRR 8.53 (3.82-19.0) 
IRR 5.42 (3.8-7.72) 
AF – atrial fibrillation, CI – confidence interval, FH – family history, FU – follow-up, HR – hazard ratio, IRR – incidence rate ratio, 
O – offspring, OR- odds ratio, P- parent, pts- patients, RR –relative risk, yrs-years  
 573 
Hyperthyroidism and other endocrine disorders  574 
Among endocrine disorders, hyperthyroidism and diabetes mellitus (see above) are commonly 575 
associated with risk of developing AF (31, 104, 249, 250), while hypothyroidism poses no or reduces risk 576 
for arrhythmia (249, 251, 252).  577 
Observational cohort and registry studies (Table 15) reported AF incidence rates of 4.6-13.8% in 578 
overt hyperthyroidism, 8.5-12.7% - in subclinical hyperthyroidism and 7.3% in high-normal  euthyroidism  579 
[based on thyroid stimulating hormone (TSH) level] (249-251, 253-257).    580 
The risk of new-onset AF in hyperthyroidism depends on the level of thyroid dysfunction. AF is 581 
increased by 42% in overt hyperthyroidism, by 31% in subclinical hyperthyroidism, and by 12% in high-582 
normal euthyroidism (249). Patients with subclinical forms are 1.68 fold more likely to develop AF during 583 
long-term follow-up, and those with suppressed TSH values have been shown to possess 2.54 fold higher 584 
risk of incident AF compared to euthyroid populations (249, 251, 253, 254, 256).  Though the evidence on 585 
risk of AF in individuals with high-normal euthyroidism is limited, the Rotterdam study demonstrated an 586 
increased risk of AF in individuals with high-normal thyroid function (based on TSH level) (257) and in 587 
subjects <65 years old with higher free thyroxine levels within normal range (258). Nonetheless the 588 
evidence on demographic and cardiovascular disease risk factors associated with AF in thyroid dysfunction 589 
is scarce. In overt hyperthyroidism, age >65years, male sex, comorbidities like coronary artery disease, 590 
chronic heart failure and valvular heart disease were reported as predictors of arrhythmia (260).  In the 591 
subclinical form, age and sex were shown to affect the incident risk of AF, being significant in all age 592 
categories in women, and young male individuals, except in the older (>65 years) male population (249). In 593 
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a recent meta-analysis (256), the risk of AF in subclinical hyperthyroidism was associated with male sex, but 594 
was not altered by the presence of cardiovascular disease or its risk factors.  In another study, subclinical 595 
hyperthyroidism was shown to be a predictor of AF in elderly individuals, along with advanced age category 596 
(>75 years), male sex, diabetes mellitus, hypertension and heart failure (257).   597 
AF risk diminishes during antithyroid treatment (249), with spontaneous restoration of sinus rhythm 598 
in about 76% of patients (259) and reduction of arrhythmia on long-term monitoring (260). Sinus rhythm 599 
restoration rates are also higher in elderly patients with overt and subclinical hyperthyroidism without 600 
cardiovascular disease and its risk factors, as compared to those with comorbidities (254). After restoration 601 
of an euthyroid state and electrical cardioversion or catheter ablation for persistent AF, long-term sinus 602 
rhythm maintenance rates have been shown to be either higher in patients with hyperthyroidism (261) or did 603 
not differ from those without history of thyroid dysfunction (262, 263). 604 
Hyperthyroidism had been long considered to be associated with higher thromboembolic risk (65), 605 
but recent studies demonstrated that thyroid disease is not an independent predictor of AF related 606 
complications such as thromboembolism and stroke (264-266). 607 
Thus, prevention of AF in overt and subclinical hyperthyroidism should include measures, such as 608 
controlling thyroid function, treatment of associated cardiovascular diseases and modification of risk factors. 609 
More research is needed regarding risk factors and prevention of AF in populations with high-normal 610 
euthyroidism based on TSH level and normal thyroid function with higher free thyroxine levels within 611 
normal range.  612 
 613 
Table 15. Risk of AF in thyroid dysfunction 
 
Study Design Subjects FU Thyroid function AF, % Risk  (95%CI) 
Selmer et al.249 
 
Cohort 586,460  
 
 
 
 
 
 
 
 
 
5.5 yrs 
 
 
 
 
 
 
Euthyroid  
Overt Hyperthyroid 
Subclinical Hyperthyroid 
Overt Hypothyroid 
Subclinical Hypothyroid 
 
TSH levels  
Reduced TSH 
Suppressed TSH 
High-normal  Euthyroid 
(TSH levels) 
2.9 
4.6 
- 
2.5 
- 
 
 
- 
- 
- 
Reference 
IRR 1.42 (1.22-1.63) 
IRR 1.31 (1.19-1.44) 
IRR 0.67 (0.5-0.9)  
IRR 0.87 (0.7-0.97)  
 
 
IRR 1.16 (0.99-1.36) 
IRR  1.41 (1.35-1.89) 
IRR 1.12 (1.03-1.21) 
Cappola et al.251 
Cardiovascular Health 
 study 
Cohort 3,233 
>65 yrs 
13 yrs Euthyroid 
Subclinical Hyperthyroid 
Overt Hypothyroid 
5.2 
8.5 
4.8 
Reference 
HR 1.98 (1.29-3.03) α 
HR 0.96 (0.52-1.79) α 
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 Subclinical Hypothyroid 3.9 HR 1.13 (0.94-1.36) α 
Frost et al.250 Cohort 40,628 30 d Overt Hyperthyoid 8.3 - 
Auer et al.254 
 
Retrospective 23,638 
elderly 
- Euthyroid 
Overt Hyperthyroid 
Subclinical Hyperthyroid 
2.3 
13.8 
12.7 
- 
- 
RR 5.2 (2.1-8.7)  
Gammage et al.255 
 
Cohort  5,860  
>65 yrs 
 
- Euthyroid 
Subclinical Hyperthyroid 
Subclinical Hypothyroid 
Serum free T4  
4.7 
9.5 
4.2 
- 
Reference 
OR 1.87(1.01-3.57) β 
- 
OR 1.09 (1.03-1.15) 
Sawin et al. 253 
Framingham Heart 
 Study 
Cohort 2,007  
 
10 yrs Euthyroid 
Reduced TSH 0.1-0.4 μU/L 
Suppressed TSH <0.1 μU/L 
8.4 
12.2 
21.3 
 
RR  1.6 (1.0-2.5) 
RR 3.8 (1.7-8.3) 
Colett et al.256 
Thyroid studies 
collaborators 
Meta-analysis 
 
52,674 
 
8.8 yrs Subclinical Hyperthyroid 
Reduced TSH  
Suppressed TSH  
- 
- 
- 
HR 1.68 (1.16-2.43) 
HR 1.63 (1.1-2.4) 
HR 2.54 (1.08-5.99) 
Heeringa et al.257 Registry 1,426 
 
8yrs 
 
High-normal Euthyroid 
(TSH levels) 
TSH - 0.4-1.04 mU/L 
7.3 HR 1.94 (1.13-3.34)γ 
 
Kim et al.252 
 Framingham Heart  
study 
Cohort 
 
5,055 
 
10yrs TSH 0.45-4.5 μU/L 
TSH  4.5-10.0 μU/L 
TSH 10.0-19.9 μU/L 
5.4 
7.0 
4.0 
Reference 
HR  1.23 (0.77-1.97)  
HR 0.57 (0.21-1.54)  
α Adjusted for age, sex, CVD, thyroid medication use, atrial size, SBP, fasting glucose. VHD, b-blockers and diuretics use 
βAdjusted for male, age>70, DM, HF, HT 
γ Adjusted for age, sex, smoking, BMI, SBP, HT, HF, MI, LVF, DM 
AF – atrial fibrillation, BMI – body mass index, CI – confidence interval,  CVD – cardiovascular disease, d – days, DM – diabetes mellitus, HF- heart 
failure, HR – hazard ratio, HT- hypertension, IRR – incidence rate ratio, LVF – left ventricular function, MI – myocardial infarction, OR – odds ratio, pts – 
patients, RR – relative risk, SBP- systolic blood pressure, TSH – thyroid stimulating hormone, VHD- valvular heart disease, yrs- years  
Definitions of thyroid dysfunction249 
Euthyroidism - TSH 0.2-5.0 mIU/L, Free thyroxine 9-22 pmol/L, Total thyroxine 60-140 mmol/L 
Overt hypothyroidism -TSH >5.0 mIU/L, Free thyroxine <9  pmol/L, Total thyroxine <60 mmol/L 
Subclinical hypothyroidism - TSH >5.0 mIU/L, Free thyroxine 9-22  pmol/L, Total thyroxine 60-140 mmol/L 
Overt hyperthyroidism – TSH<0.2 mIU/L, Free thyroxine >22  pmol/L, Total thyroxine >140 mmol/L 
Subclinical hyperthyroidism - TSH <0.2 mIU/L, Free thyroxine 9-22  pmol/L, Total thyroxine 60-140 mmol/L 
TSH level dependent thyroid dysfunction249 
Euthyroidism - TSH 0.4-5.0 MiU/L, Free thyroxine 9-22 pmol/L, Total thyroxine 60-140 mmol/L 
High normal euthyroidism - TSH 0.2-0.4 mIU/L, Free thyroxine 9-22 pmol/L, Total thyroxine 60-140 mmol/L 
Subclinical hyperthyroidism (reduced TSH) - TSH 0.1-0.2 mIU/L, Free thyroxine 9-22 pmol/L, Total thyroxine 60-140 mmol/L 
Subclinical hyperthyroidism (suppressed TSH) - TSH <0.1 mIU/L, Free thyroxine 9-22 pmol/L, Total thyroxine 60-140 mmol/L 
  614 
Electrophysiological considerations 615 
Atrial premature beats triggering AF 616 
Atrial fibrillation can be maintained by rapid focal firing or by reentrant activity. The actual mechanism by 617 
which triggers (ectopic beats) initiate AF is unclear, but an important topic of research. Prior reports have 618 
mapped spontaneous ectopic triggers for AF and demonstrated their spatial diversity in both atria and 619 
prematurity in rate (267). Several mechanisms produce abnormal impulse formation that can cause focal 620 
ectopic activity: abnormal automaticity and triggered activity. Abnormal automaticity relies on an increased 621 
phase 4 depolarization in cells that normally have a flat phase 4. The (upregulation of the) pacemaker 622 
current If (funny current) may play an important role in this mechanism. 623 
Triggered activity consists of depolarizations occurring after the action potential: delayed after 624 
depolarizations (DADs) or within the action potential: late phase 3 early after depolarizations. These triggers 625 
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often originate from predilected sites in the atria, such as the ostia of the pulmonary vein sleeves (267). 626 
DADs are thought the most common cause of focal atrial ectopic firing and are caused by diastolic Ca
++
 leak 627 
from the sarcoplasmic reticulum via SR Ca
++ -
release channels (RyR2) and the Na
+
/Ca
++
 exchange (NCX) 628 
(268).  629 
To maintain AF, these ectopic beats must be sustained to produce rapid driver activity or form the trigger to 630 
initiate reentry in a vulnerable substrate. AF remodels the atrial electrical properties to promote both 631 
initiation and propagation. It is well known that electrical remodeling consists of shortening of the duration 632 
of the action potential and depressed intracellular Ca
++
 transients. Besides the involvement of the regular ion 633 
channels, also the INa late current plays a possible role.  634 
Structural remodeling plays another important role in the initiation and maintenance of AF (269). Various 635 
pathways play a role including the RAAS, inflammation and fat deposition leading to enlarged atria, 636 
hypertrophy, fibrosis, and myolysis (270-276). Indeed, the first manifestation of AF usually occurs after 637 
years of atrial remodeling (273). Once AF develops, it causes marked changes in atrial electrophysiology 638 
(„electrical remodeling‟) in addition to further deterioration of the structural remodeling processes, 639 
constituting a vicious cycle in which „AF begets AF‟ (271), making it challenging to restore and maintain 640 
sinus rhythm (273, 274).    641 
Molecular Mechanisms 642 
Abnormal cellular Ca
++
 handling is typically seen in AF patients. Defective Ca
++
 handling promotes 643 
spontaneous ryanodine receptor (RyR2) mediated Ca
++
 release in atrial cells of patients with AF. 644 
Phosphorylation of RyR2 and CAMKII is increased in AF. Increases in NCX expression/activity are also 645 
common noted in AF. 646 
Supraventricular tachyarrhythmias causing AF 647 
Supraventricular tachyarrhythmias (SVT) and pre-excitation may associate with AF (275-278). In 169 648 
paroxysmal SVT outpatients, AF incidence was 19% over 2.5 years, assessed by remote monitoring (Fig. 1) 649 
(277). Atrial flutter and AF coexist even more often, one arrhythmia potentially reinforcing the other (279). 650 
Finally, flutter is frequently accompanied by atrioventricular nodal re-entry tachycardia (AVNRT) (280). 651 
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Causal mechanisms include tachycardia related atrial ischemia or dispersion of conduction and 652 
refractoriness, which can be facilitated by background atrial remodeling. Enhanced vagal tone is another 653 
mechanism (281). Digitalis may cause shortening of atrial refractoriness (282) and also associate SVT or 654 
atrial flutter with AF. The same may hold for adenosine, which may elicit AF when given for termination of 655 
SVT, and potentially cause hemodynamic deterioration (283). Due to conduction slowing, flutter may 656 
emerge under drug treatment for AF through activation of a sleeping circuit, seen especially with flecainide 657 
or propafenone (class-Ic flutter) (284). Late onset AVNRT may occur upon cardiovascular ageing, in turn 658 
producing triggers and substrate for both AVNRT, as well as AF and flutter (285). Similarly, atrial 659 
remodeling  (e.g. in the setting of hypertension) may connect atrial tachycardia and atrial flutter to AF. Last, 660 
but not least, AF and SVT may also simply associate due to presence of both arrhythmia mechanisms 661 
including frequent pulmonary vein ectopy, as part of paroxysmal AF, but triggering the SVT substrate 662 
meanwhile. 663 
 664 
Figure 1. Graph showing time to occurrence of symptomatic atrial fibrillation in all 169 patients with 665 
paroxysmal supraventricular tachycardia. Y-axis reflects percentage of patients free from atrial fibrillation. 666 
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(Reprinted from reference 277: J Am Coll Cardiol Vol.25, Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, 667 
Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. number, p. 668 
984-8, Copyright 1995, with permission from Elsevier) 669 
 670 
In pre-excitation syndrome, the very presence of the accessory atrioventricular pathway (i.e. in the 671 
absence of atrial remodeling like in „classic‟ AF) has been associated with local atrial arrhythmogenesis and 672 
hence AF. Conduction dispersion emerges during retrograde pathway conduction after ventricular premature 673 
beats or during orthodromic tachycardia. Asymptomatic pre-excitation usually is not associated with AF, 674 
although younger patients as well as those with inducible SVT or AF and those with a short anterograde 675 
refractory period may be at risk (286). AF and pre-excitation, together with premature conduction disease, 676 
may occur in a rare genetic form of hypertrophic cardiomyopathy due to AMP kinase gene mutation 677 
deregulating cellular energy homoeostasis (287).  678 
When PAF and SVT associate, medical (including upstream anti-remodeling) therapy may apply for 679 
both although ablation of both mechanisms seems most appropriate. Ablation of SVT or flutter may abolish 680 
AF or make it better amenable to rhythm control, although frequently electrophysiologists will perform 681 
pulmonary vein isolation at the same time. Ablation of the accessory pathway, in patients with overt pre-682 
excitation suffering from AF, may prevent further AF attacks (288) and is the preferred treatment also to 683 
prevent rare sudden death due to ventricular fibrillation. If these patients refuse ablation or complications are 684 
expected (e.g. atriovenricular block), then medical therapy may be indicated (286, 289). Usually flecainide 685 
or propafenone are prescribed and amiodarone may be needed in the presence of concurrent cardiac disease. 686 
After ablation of class Ic flutter it is advocated to continue drug treatment for suppression of the initial AF 687 
although after isthmus ablation AF attacks may subside spontaneously. To avoid repeat procedures, SVT 688 
mechanisms should be checked electrophysiologically during any AF ablation, especially in the younger 689 
non-remodelled AF patients (Fig. 2). 690 
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 691 
Figure 2. Management of supraventricular tachycardias causing AF 692 
(AF – atrial fibrillation, AAD – antiarrhythmic drug, PAF – paroxysmal AF, SVT – supraventricular tachycardia) 693 
 694 
Post-operative atrial fibrillation  695 
AF after cardiac surgery occurs in approximately 30% of patients (290), and is also frequent after 696 
thoracic surgery. This arrhythmia is associated with higher occurrence of heart failure and stroke, both 697 
resulting in increased hospitalization and healthcare costs (291); and also  correlating with a higher rate of 698 
other serious complications [increased risk of in-hospital morbidity and mortality, and increased long-term 699 
risk of stroke] (292). Post-operative AF usually is developed between day 1 and 4 after surgical intervention. 700 
The mechanisms underlying the development of AF after cardiac surgery are not completely understood, but 701 
are thought to be multifactorial (291). Numerous predisposing factors such as advanced age, hypertension, 702 
diabetes, left atrial enlargement, left ventricular hypertrophy, type of intervention and presence of cardiac 703 
valvular disease, intraoperative and post-operative factors such as atrial injury or ischemia, can favor the 704 
development of post-operative AF (293).  705 
Different drugs have been investigated to prevent post-operative AF. Centrally-acting -adrenergic 706 
receptor blocking agents tend to reduce sympathetic efferent activity and promote cardiac vagal outflow 707 
(294). Current guidelines strongly recommend using -blockers to reduce post-operative AF incidence (65) 708 
and for that reason, preoperative -blocker administration is standard in all patients without 709 
contraindications. Indeed, the European guidelines recommend that treatment should be started at least 1 710 
week before surgery with a 1-blocker without intrinsic sympathomimetic activity (65). A large meta-711 
analysis of 27 randomized controlled trials with 3,840 patients, reported that the incidence of post-operative 712 
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AF in control patients was 33% compared to 19% in those taking -blockers, although an inexplicable and 713 
marked heterogeneity was found between trials (295). The importance of -blockers is also affirmed by the 714 
two to five-fold increase in AF after cardiac surgery, when -blockers are discontinued postoperatively 715 
(296). 716 
The effectiveness of sotalol vs. placebo and sotalol vs. conventional -blockers in preventing AF 717 
after surgery has been analyzed in several clinical trials. A recent meta-analysis (297) analyzed 8 trials 718 
(1,294 patients in total) evaluating the effect of sotalol to reduce post-operative AF, and demonstrated a 719 
reduction in AF incidence (37% in placebo group vs. 17% in sotalol group) with no significant heterogeneity 720 
between trials. Sotalol and other  -blockers were compared directly in 4 trials including 900 patients (295). 721 
Once again, sotalol reduced the incidence of postoperative AF from 22% in the other  -blocker group to 722 
12% in the sotalol group with no significant heterogeneity. However, the use of sotalol places patients at risk 723 
of bradycardia and torsade de pointes, especially in those with electrolyte disturbances,  reason why its use 724 
in post-operative AF is limited (65). 725 
Several studies have analyzed the impact of amiodarone on post-operative AF, with more than 10 726 
randomized placebo-controlled trials. In a recent meta-analysis (297), prophylactic amiodarone decreased 727 
the incidence of postoperative AF (OR 0.43; 95% CI 0.34–0.54) and significantly shortened the duration of 728 
hospital stay, reduced the incidence of stroke and of post-operative ventricular tachyarrhythmia, but not 729 
post-operative mortality (298). European guidelines recommend considering preoperative amiodarone for 730 
patients at high risk for post-operative AF (65). 731 
It is recognized that the use of statins is associated with a 22–34% lower risk of post-operative AF 732 
(65). The largest and most robust trial of atorvastatin carried out to date, the Atorvastatin for Reduction of 733 
Myocardial Dysrhythmia After cardiac surgery study (ARMYDA-3) (299), demonstrated that atorvastatin 734 
treatment conferred a 61% reduction in risk of post-operative AF in multivariable analyses.  A recent large 735 
randomised trial did not show beneficial effects of rosuvastatin on incidence of complications or AF after 736 
cardiac surgery (300). 737 
Other drugs have been studied (297, 301), but most show conflicting results. For example, no 738 
significant effect of RAAS related medications on the occurrence of AF following cardiac surgery (291) and 739 
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safety concerns about the potential risk of associated renal dysfunction. A meta-analysis demonstrated a 740 
significant reduction in post-operative AF using corticosteroids (302), but we should take into account the 741 
potential adverse effects on glucose metabolism, wound healing, and infection. Other drugs explored 742 
included magnesium supplements, colchicine, non-steroidal anti-inflammatory drugs and antioxidant agents 743 
(i.e. polyunsaturated fatty acids or N-acetylcysteine) (301). 744 
Current European guidelines recommend -blockers and amiodarone as prophylactic therapies for 745 
post-operative AF. However, new pharmacologic agents, with anti-inflammatory and remodeling properties 746 
could take a place in the prevention of post-operative AF. Further research in this field is needed.  747 
 748 
Upstream therapies to prevent AF 749 
Upstream therapy refers to the use of non-ion-channel antiarrhythmic drugs that modify the atrial substrate 750 
upstream of AF to prevent new-onset AF (i.e. primary prevention) or recurrent AF (i.e. secondary 751 
prevention). It includes treatment with RAAS blockers [ACEIs, ARBs, and mineralocorticoid receptor 752 
antagonists (MRAs)], statins and possibly n-3 PUFAs (303, 304). RAAS blockers may prevent or reduce 753 
atrial structural remodeling by decreasing fibrosis and improving hemodynamics. Interestingly, recent data 754 
support the favorable effects of physical activity, i.e. moderate exercise on AF burden (226).  755 
Upstream therapy has been encouraging in animal experiments, hypothesis-generating small clinical 756 
studies and primary prevention studies (303, 304). However, only few data support its beneficial effect for 757 
secondary prevention of AF. ACEIs and ARBs seem valuable, especially when added to amiodarone (274, 758 
305). Mineralocorticoid receptor antagonists may be even more effective in preventing AF recurrences but 759 
few data are available (306, 307).  760 
Statins, known for their lipid-lowering capacities, have pleiotropic properties such as reduction of 761 
inflammation and oxidative stress. Through these properties, statins may play a protective role against AF 762 
development. However, results regarding effectiveness of statins have been inconclusive (304).  763 
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The effects of PUFAs have been well demonstrated in animal model, but limited evidence in 764 
secondary prevention of AF is available (303, 304).  765 
Favourable effects of lifestyle changes, including moderate exercise, have been demonstrated in 766 
selected patients (26, 27, 147, 201). In a recent randomized trial, in obese AF patients, weight management, 767 
including physical activity and counselling, was compared to general lifestyle advice (26). In addition to a 768 
significant reduction of body mass index, AF symptoms and burden were significantly reduced in the 769 
aggressive weight management group. This finding was confirmed in the Long term Effect of Goal directed 770 
weight management on AF Cohort: a 5 Year follow-up (LEGACY) trial, again in obese AF patients (28). 771 
Progressive weight loss was associated with a reduced AF burden and symptoms and, interestingly, left 772 
atrial volume. 773 
Overall, upstream therapy may be effective in primary prevention. The disappointing results 774 
regarding secondary prevention  of AF may have been caused by inclusion of patients in whom the extent of 775 
remodeling was too severe and irreversible due to a long history of AF and underlying diseases (273, 274). 776 
Inclusion of patients, in whom remodeling processes are less advanced, may improve outcome, in addition 777 
to tailoring certain upstream therapies to distinct patient groups (e.g. lifestyle changes in obese inactive 778 
patients). 779 
 780 
Risk factors leading to AF development as risk factors for thromboembolic complications 781 
Stroke prevention is central to the management of AF (308), and many of the risk factors leading to 782 
AF development are also risk factors for its thromboembolic complications. Whilst AF increases the risk of 783 
stroke 5-fold, this risk is not homogeneous and depends on the presence of various stroke risk factors (309). 784 
Some risk factors are independent predictors of stroke risk, and have been used to formulate various stroke 785 
risk stratification schemes, such as the CHA2DS2-VASc score, which is now recommended in guidelines 786 
(310). There are also various stroke risk modifiers, such as obstructive sleep apnea (311) and renal 787 
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impairment (312), that have been associated with an increased stroke risk per se, although their additive 788 
predictive (and practical) value over and above validated stroke risk scores is less certain. Whether treatment 789 
of sleep apnea with continuous positive airway pressure reduces stroke risk is unproven (311). 790 
Some risk factors within the CHA2DS2-VASc score, such as age, prior stroke or thromboembolism, 791 
vascular disease and female sex, are non-modifiable. Also, prior heart failure especially if associated with a 792 
hospital admission with decompensation, confers an excess of stroke risk (313). Hence, efforts to minimize 793 
hospitalisations and decompensation of heart failure may help.  Diabetes mellitus is less modifiable, but 794 
duration of diabetes may predispose to an even higher risk of stroke and thromboembolism 107). 795 
In a systematic review of stroke risk factors, a history of hypertension or uncontrolled hypertension 796 
conferred an increase in stroke risk (309), but clearly, well-controlled hypertension has a lower risk of stroke 797 
compared to uncontrolled hypertension (314). Hypertension is also the commonest comorbidity associated 798 
with AF. Thus, patients with AF should have blood pressures approximately 130/80mmHg, reflecting the 799 
fact that AF could be considered a manifestation of hypertensive target organ damage, and given that stroke 800 
risk starts to rise beyond SBPs of 130mmHg (314). 801 
Other potentially modifiable risk factors such as obesity, smoking and alcohol excess have been 802 
related to an increased risk of stroke and mortality (33, 315, 316), although  intervention studies to show 803 
how these would successfully decrease the risk of stroke in AF are lacking. Data from cohort studies very 804 
recently indicated that weight reduction and improvement in physical fitness may reduce the recurrence of 805 
AF (27). Also, rhythm control measures, such as cardioversion and ablation, may help in symptom 806 
management and improve functional status, but randomized trials, clearly showing that such interventions 807 
reduce stroke in a broad range of unselected AF cohorts are lacking (317). Observational data, in selected 808 
cohorts, suggest that successful catheter ablation may be associated with a lowered stroke risk (318) but, 809 
given that asymptomatic recurrences and late recurrence are recognized phenomena, guidelines recommend 810 
continuation of oral anticoagulation (OAC), in patients with a CHA2DS2-VASc score of ≥2, irrespective of 811 
apparent success of rhythm control (317). 812 
 Page 49 of 82 
Modifiable factors to reduce the risk of stroke can include attention to quality of anticoagulation 813 
control for a patient taking a VKA (e.g., warfarin).  The quality of anticoagulation control is usually 814 
quantified by the average time in therapeutic range (TTR) and a TTR of >70% is recommended (319). 815 
However, TTR can be influenced by various clinical risk factors, especially in inception cohorts where 816 
warfarin is introduced (320). Thus, in newly diagnosed and previously anticoagulated naïve AF patients, a 817 
„trial of warfarin‟ prior to considering a non-VKA oral anticoagulant (NOAC) is not recommended given 818 
that TTR is likely to be subtherapeutic in the early phase of warfarin initiation, leading to an increased risk 819 
of stroke (321).  The SAMe-TT2R2 score (322) has been proposed to help decision-making between patients 820 
who are likely to do well on a VKA with high TTR (i.e. SAMe-TT2R2 score 0-2) and those unlikely to do 821 
well on a VKA with poor TTR (SAMe-TT2R2 score >2), where a NOAC would be a better first option (323, 822 
324). Thus, simple clinical decision making, based on clinical risk factors that influence poor TTR as a 823 
stroke risk factor (within the SAMe-TT2R2 score), can help inform treatment decisions that would reduce the 824 
likelihood of labile INRs, and its adverse consequences such as stroke, bleeding and death (325). 825 
 826 
Patient values/preferences 827 
Many of the risk factors for the development of AF are to a certain extent preventable and/or 828 
modifiable via lifestyle choices such as diet, smoking, alcohol, recreational drug use, physical activity, 829 
maintenance of a healthy weight, and adherence to medication to control concomitant conditions 830 
(hypertension, diabetes, hyperthyroidism etc.) and therefore potentially under individuals‟ conscious control 831 
(326).  In addition, risk factors are likely to be cumulative in increasing risk of incident AF  (98, 111, 115). 832 
However, an individual‟s ability to „control‟ these factors may be limited by socioeconomic circumstances, 833 
access to healthcare and medications, and health literacy etc. Therefore, primary prevention of disease 834 
requires greater public awareness of the causes and consequences of the disease and how a person can 835 
modify his/her own risk of developing it. Thus, improving the general populations‟ understanding and 836 
perception of AF (what it is, how it develops, associated stroke risk), of how their lifestyle impacts their risk 837 
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of developing AF, and identifying strategies to change their health beliefs and health behaviours to reduce 838 
their risk of progressing to AF, requires both an individual approach plus global public health campaigns. 839 
Since lifestyle choices have significant impacts on all diseases, healthcare professionals should utilise 840 
contacts with patients to discuss diet, smoking, alcohol/drug use, and exercise, offer appropriate education, 841 
advice, and intervention(s), and support people to adopt and maintain health-promoting behaviours to help 842 
reduce their risk of developing AF (and other diseases). 843 
 844 
Table 16a. Consensus statements on AF prevention I: risk factors and lifestyle modification 845 
Risk factor/ 
trigger 
Recommendations for clinical practice Recommendations for research 
Obesity Inform overweight and obese patients of greater risk of developing AF and a 
subsequent risk of stroke and death. 
Assess BMI and start lifestyle programs if BMI is overweight or obese 
 
More studies are needed on how to effectively 
prevent weight gain and promote weight loss in 
individuals who are overweight or obese 
More randomized controlled studies with long-term 
follow-up (>5 years) are needed to clarify the 
obesity paradox. 
General dietary 
considerations 
Recommend healthy nutrition and lifestyle to reduce risk of AF 
Mediterranean diet enriched with olive oil may  reduce risk of AF and its 
complications 
 
More studies are needed on: 
The effect of unhealthy nutrition on risk of AF   
Whether modification of diet reduces risk of 
arrhythmia 
Blood lipids, 
fish 
consumption 
Inform patients with low HDL and high triglyceride levels of risk of AF and 
its complications 
Recommend to patients with abnormal blood lipids consumption of a diet  
“that emphasizes intake of vegetables, fruits, and whole grains; includes low-
fat dairy products, poultry, fish, legumes, non-tropical vegetable oils, and 
nuts; and limits intake of sweets, sugar-sweetened beverages, and red 
meats”64 
Recommend combination of diet with moderate  physical activity and 
maintenance of a healthy lifestyle and weight 
Lacking direct evidence, more studies are needed 
to define whether modification of blood lipids 
reduces the risk of AF.   
Obstructive 
sleep apnea 
Inform patients with obstructive sleep apnea that there is a greater risk of 
developing AF and their subsequent risk of stroke and death.  
Assess by anamnesis (snoring, daytime fatigue) the possibility of OSA. 
Refer to specialised clinic, as needed. 
More studies are needed:   
To investigate how comorbidity in patients with 
obstructive sleep apnea affects the risk of AF.  
To show the benefit of diagnostic efforts and the 
effect of treatment with CPAP.  
On adequate assessment of presence of OSA in AF 
population. 
To show reduced risk of AF in well powered RCTs 
using systematic therapeutic approach together 
with other lifestyle changes  
Hypertension Uncontrolled blood pressure is associated with AF risk 
Adequately assess patients at risk  
Control BP to reduce AF risk  
 
Additional well-conducted secondary AF 
prevention trials will be important to define target 
SBP optimal to prevent AF 
Implement in RCTs together with other lifestyle 
management 
 
Diabetes 
mellitus 
Longer duration of diabetes and worse glycemic control are associated with 
increased  AF risk 
Control diabetes to reduce AF risk   
More research is needed on the effect of glycemic 
control on AF risk in patients with diabetes 
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Risk factor/ 
trigger 
Recommendations for clinical practice Recommendations for research 
Tobacco 
smoking 
Intensively encourage children, young and older adults not to begin smoking. 
In individuals who smoke support smoking cessation to prevent AF 
incidence, recurrence, symptoms, and complications. 
 
Primordial prevention. Support efforts to prevent the uptake of tobacco 
smoking. 
Primary prevention. Encourage individuals to quit smoking. 
Secondary prevention. In individuals with AF promote efforts to quit 
smoking to improve AF frequency, duration, and symptoms 
 
Investigate whether electronic cigarettes and 
second hand smoke are associated with an 
increased risk of new-onset AF, and in individuals 
with prevalent AF, whether electronic cigarettes 
and second hand smoke are associated with AF 
recurrence and AF symptoms. 
In individuals with AF, examine the efficacy and 
effectiveness of smoking cessation interventions to 
decrease the risk of stroke, myocardial infarction, 
chronic kidney disease, dementia, and all-cause 
mortality. 
Air pollution No association with chronic exposure; patients prone to AF should refrain 
from severe pollution exposure.  
Overall data are scarce and should be increased 
specifically aimed at incidence of AF in patients 
with known cardiac disease. 
Caffeine  No increase in risk, rather a reduced association, even for heavy 
consumption. 
Data should be extended to randomized 
intervention studies addressing caffeine 
consumption in patients with paroxysmal AF 
Alcohol Moderate-heavy and binge drinking increases AF risk 
To reduce AF risk:  
Recommend to avoid binge drinking (>4 drinks in women and >5 drinks in 
men on a single occasion) 
Recommend to refrain consumption to no more than 2 drinks per day for men 
and 1 drink per day for women 
Obtain a detailed history on alcohol consumption  
Provide appropriate counseling to reduce alcohol consumption in patients 
with AF  
More intervention studies are needed on the effect 
of alcohol consumption reduction on AF risk 
Medications Many drugs increase AF risk. 
 In patients with new-onset AF, review the pharmacological history to 
identify whether any of the prescribed drugs may cause the arrhythmia.   
More research on the effects on AF incidence for 
drug induced new-onset AF is needed, as many 
studies show conflicting results. 
Also more research is needed on which 
medications cause increased risk of AF. 
Recreational 
drugs 
 
Recreational drugs (cannabis, ecstasy and anabolic androgenic steroids) may 
increase risk of AF.  
Examine for recreational drug abuse in new-onset AF  
Encourage avoidance of recreational drugs. 
More research is needed on the effect of illicit 
drugs, particularly cannabis, on new-onset AF, as 
most of the evidence is from case reports 
Psychological 
distress 
Identify significant psychological distress, particularly depression and 
anxiety, and treat appropriately to reduce the likelihood of adverse lifestyle 
choices (smoking, excessive alcohol intake, poor diet, physical inactivity) 
and poorer adherence to medication and lifestyle modification, all of which 
may increase the likelihood of development of other risk factors for AF, and 
hence predispose people to incident AF and other chronic diseases. 
Further investigation of the impact of 
psychological distress on the development of AF in 
more diverse populations is warranted since the 
current limited evidence is based predominantly on 
white, middle-class, and middle-aged cohorts, and 
is only evident in men. 
Physical 
activity 
Recommend daily moderate exercise to reduce risk of AF Role of physical activity clearly warrants further 
research, plus genetics involved in AF in excessive 
sports 
AF – atrial fibrillation, BMI – body mass index, BP – blood pressure, CPAP – continuous positive airway pressure, HDL – high-densiy lipoprotein 
cholesterol, OSA – obstructive sleep apnea, RCT – randomised controlled trial, SBP – systolic blood pressure  
 846 
Table 16b. Consensus statements on AF prevention II: management of associated conditions 847 
Risk factor/ 
trigger 
Recommendations for clinical practice Recommendations for research 
Hyperthyroidism Overt and subclinical hyperthyroidism increase AF risk  
Control thyroid function in patients at risk of AF 
Treat associated cardiovascular diseases and consider modification of risk 
factors 
More research is needed regarding risk 
factors and prevention of AF in populations 
with high-normal thyroid function (based 
on TSH level) and individuals with higher 
level of free thyroxin within normal range.   
Supraventricular 
tachyarrhythmias 
and paroxysmal 
AF 
In patients with SVT and paroxysmal AF: 
Ablate SVT, continue antiarrhythmic drugs or ablate AF as needed. 
Checking for potential SVT substrate should be considered in patients with 
isolated PAF referred for ablation 
Additional studies on prevention of AF in 
patients with SVT are needed 
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Risk factor/ 
trigger 
Recommendations for clinical practice Recommendations for research 
Postoperative AF Beta-blockers and amiodarone are indicated for prophylaxis of 
postoperative AF 
More research is needed on use of 
pharmacological agents with anti-
inflammatory and anti-remodeling 
properties for prevention of postoperative 
AF 
Upstream 
therapies 
-  Long term effects of long-term secondary 
prevention with upstream therapies  starting 
early after onset of AF 
AF –atrial fibrillation, PAF – paroxysmal atrial fibrillation, SVT – supraventricular tachycardia, TSH – thyroid stimulating hormone 
 848 
 849 
 850 
Conclusions 851 
In the present document, the determinants and triggers of atrial fibrillation (AF) are extensively 852 
discussed and it appears clear that prevention of this disorder requires a tailored approach to the individual 853 
patient.  Moreover, certain modifiable risk factors, such smoking, alcohol abuse and lack of physical activity 854 
are deemed important components of a preventive strategy (33, 315, 316).  855 
In order to reduce the risk of AF, both an individual approach and global public health campaigns are 856 
required.  857 
Many of the risk factors for AF are preventable and/or modifiable via lifestyle choices. As explained, 858 
modifying an inappropriate diet, quitting smoking, abstaining from alcohol and recreational drugs, and 859 
participating in regular physical activity programs are efficient strategies under the patient‟s control.  860 
A lifetime approach to cardiovascular risk modification is required (Fig. 3). General physicians have 861 
a relevant role in this strategy, by monitoring their patients closely and  adopting a lower threshold for 862 
educational intervention. A particular relevance to the scope is assigned to the implementation of nutritional 863 
interventions and to promote regular exercise programs and sport participation. However, the greatest effort 864 
should be paid by policy makers in order to improve the population‟s capability to achieve and maintain a 865 
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healthy cardiovascular lifestyle. The most adverse risk profile is actually prevalent among individuals with 866 
low socioeconomic status, poorer educational attainment, and limited access to health care.  867 
The prevention of AF, more than other cardiovascular disorders, requires an approach that targets the 868 
global population, and a new political vision in the management of the health care system. In a society with 869 
available limited financial resources, it appears wise to modify the risk factors and quality of life of the 870 
largest majority of general population, more than developing sophisticated devices to shortly prolong the life 871 
of a few terminal patients. 872 
Finally, special attention should be paid to the adolescent and young generations, who paradoxically are not 873 
at low cardiac risk, because of the epidemic incidence of obesity, inappropriate nutritional behavior, 874 
smoking and alcohol abuse, and a widespread sedentary lifestyle. 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
 Page 54 of 82 
 886 
 887 
 888 
 889 
 890 
 891 
 892 
 893 
 894 
 895 
 896 
 897 
 898 
 899 
 900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
Figure 3. Lifetime approach to primary prevention of AF 912 
(AF – atrial fibrillation) 913 
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